

Mobile phase: MeOH containing 10 mM ammonium perchlorate and 1 mL/L 100 mM NaOH in MeOH, pH 6.7

Flow rate: 2

Injection volume: 20

Detector: E, LeCarbone, V25 glassy carbon electrode, + 1.2 V

CHROMATOGRAM

Retention time: 2.8

OTHER SUBSTANCES

Also analyzed: acebutolol, acepromazine, acetophenazine, N-acetylprocainamide, albuterol, alprenolol, amethocaine, amiodarone, amitriptyline, antazoline, atenolol, azacyclonal, bamethan, benactyzine, benperidol, benzethidine, benzocaine, benzocetamine, benzphetamine, benzquinamide, bromhexine, bromodiphenhydramine, bromperidol, brompheniramine, brompromazine, buclizine, bufotenine, bupivacaine, buprenorphine, butacaine, butethamate, chlorcyclizine, chlorpheniramine, chlorphenoxamine, chlorprenaline, chlorpromazine, chlorprothixene, cimetidine, cinchonidine, cinnarizine, clemastine, clomipramine, clonidine, cocaine, cyclazocine, cyclizine, cyclopentamine, cyproheptadine, deserpidine, desipramine, dextromoramide, dextropropoxyphene, dicyclomine, diethylcarbamazine, diethylpropion, diethylthiambutene, dihydroergotamine, dimethindene, dimethothiazine, diphenhydramine, diphenoxylate, dipipanone, diprenorphine, dipyrindamole, disopyramide, dothiepin, doxapram, doxepin, doxylamine, droperidol, ephedrine, ergocornine, ergocristine, ergocristinine, ergocryptine, ergometrine, ergosine, ergosinine, ergotamine, ethalpropazine, etorphine, etoxeridine, fenethazine, fenfluramine, fenoterol, fentanyl, flavoxate, fluopromazine, flupenthixol, fluphenazine, flurazepam, haloperidol, hydroxyzine, hyoscine, ibogaine, imipramine, indapamine, iprindole, isothipendyl, isoxsuprine, ketanserine, laudanosine, lidocaine, lofepramine, loxapine, maprotiline, mecamlamine, meclophenoxate, meclozine, medazepam, mephentermine, mepivacaine, meptazinol, mepyramine, mesoridazine, metaraminol, methadone, methamphetamine, methapyrilene, methdilazene, methotrimeprazine, methoxamine, methoxyphenamine, methoxypromazine, methylephedrine, methylergonovine, methysergide, metoclopramide, metopimazine, metoprolol, mianserin, morazone, nadolol, nalorphine, naloxone, naphazoline, nicotine, nifedipine, nomifensine, nortriptyline, noscapine, orphenadrine, oxeladin, oxprenolol, oxymetazolin, papaverine, pargyline, pecazine, penbutolol, pentazocine, penthienate, pericyazine, perphenazine, phenadoxone, phenampromide, phenazocine, phenbutrazate, phendimetrazine, phenelzine, phenglutarimide, phenindamine, pheniramine, phenmetrazine, phenomorphan, phenoperidine, phenothiazine, phenoxybenzamine, phentolamine, phenylephrine, phenyltoloxamine, physostigmine, piminodine, pimoziide, pindolol, pipamazine, pipazethate, piperacetazine, piperidolate, pipradol, pirenzepine, piritramide, pizotifen, practolol, pramoxine, prazosin, prenylamine, prilocaine, primaquine, proadifen, procainamide, procaine, prochlorperazine, procyclidine, proheptazine, prolintane, promazine, promethazine, pronethalol, properidine, propiomazine, propranolol, prothipendyl, protriptyline, proxymetacaine, pseudoephedrine, pyrimethamine, quinidine, quinine, ranitidine, rescinnamine, sotalol, tacrine, terazosin, terbutaline, terfenadine, thenyldiamine, theophylline, thiethylperazine, thiopropazate, thioproperazine, thioridazine, thiothixene, thonzylamine, timolol, tocinide, tolpropamine, tolycaine, tranlylcypromine, trazodone, trifluoperazine, trifluoperidol, trimeprazine, trimethobenzamide, trimethoprim, trimipramine, tripeleppamine, triprolidine, tryptamine, verapamil, xylometazoline

REFERENCE

Jane, I.; McKinnon, A.; Flanagan, R. J. High-performance liquid chromatographic analysis of basic drugs on silica columns using non-aqueous ionic eluents. II. Application of UV, fluorescence and electrochemical oxidation detection, *J. Chromatogr.*, **1985**, *323*, 191–225.

Trimeprazine


Molecular formula: C₁₈H₂₂N₂S

Molecular weight: 298.45

CAS Registry No.: 84-96-8, 4330-99-8 (tartrate)

Merck Index: 9834

Lednicer No.: 1 378



SAMPLE

Matrix: bile, blood, gastric contents, tissue, urine

Sample preparation: Homogenize tissue with 12 volumes water. 1 mL Whole blood, urine, bile, gastric contents, or tissue homogenate + 5 mL n-heptane:isoamyl alcohol 98.5:1.5 + 500 μ L pH 8.5 saturated sodium carbonate buffer + 20 μ L 100 μ g/mL prochlorperazine in MeOH, agitate, centrifuge. Remove the organic layer and evaporate it to dryness, reconstitute the residue in 100 μ L MeCN, inject a 70 μ L aliquot.

HPLC VARIABLES

Column: 250 \times 3.2 5 μ m Spherisorb CN

Mobile phase: MeCN:15 mM pH 6.5 sodium acetate buffer 95:5

Flow rate: 1

Injection volume: 70

Detector: UV 254

CHROMATOGRAM

Internal standard: prochlorperazine

Limit of detection: 20 ng/mL

KEY WORDS

whole blood; brain; liver; kidney; heart; muscle

REFERENCE

Kintz,P.; Berthault,F.; Tracqui,A.; Mangin,P. A fatal case of alimemazine poisoning, *J.Anal.Toxicol.*, **1995**, *19*, 591-594.

SAMPLE

Matrix: blood

Sample preparation: 10 mL Plasma or whole blood + 1 mL 1 M NaOH, extract twice with 10 mL hexane for 30 min. Remove the organic layers and evaporate them to dryness under a stream of nitrogen, reconstitute the residue in 1 mL 100 mM HCl, add 5 mL chloroform, vortex for 1 min, centrifuge. Remove a 4.5 mL aliquot of the organic layer and evaporate it to dryness, reconstitute the residue in 100 μ L mobile phase, inject a 50 μ L aliquot.

HPLC VARIABLES

Column: 10 μ m Micropak CN (Varian)

Mobile phase: MeCN:20 mM ammonium acetate 90:10

Flow rate: 2.5

Injection volume: 50

Detector: UV 254 or E, Bioanalytical Systems LC4A, glassy carbon electrode +0.9 V, Ag/AgCl reference electrode

CHROMATOGRAM

Retention time: 6.6

Limit of detection: 0.1 ng/mL (electrochemical)

OTHER SUBSTANCES

Extracted: amitriptyline, butaperazine, chlorpromazine, fluphenazine, promazine, promethazine, thioridazine, trifluoperazine

Simultaneous: acetophenazine, benztropine, haloperidol, imipramine, mesoridazine, nortriptyline, orphenadrine, piperacetazine, thiothixene, trihexyphenidyl

Interfering: carphenazine, trifluopromazine

KEY WORDS

plasma; whole blood

REFERENCE

Curry,S.H.; Brown,E.A.; Hu,O.Y.-P.; Perrin,J.H. Liquid chromatographic assay of phenothiazine, thioxanthene and butyrophenone neuroleptics and antihistamines in blood and plasma with conventional and radial compression columns and UV and electrochemical detection, *J.Chromatogr.*, **1982**, *231*, 361-376.

SAMPLE

Matrix: blood

Sample preparation: Plasma. 1-5 mL Plasma + 1 mL 1 M NaOH, extract with mixed hexanes for 30 min, centrifuge. Remove a 9 mL aliquot of the hexane layer and evaporate it to dryness under a stream of nitrogen at 30°, dissolve residue in 100 µL mobile phase, inject a 50 µL aliquot. Whole blood. 10 mL Whole blood + 1 mL 1 M NaOH, extract with 15 mL mixed hexanes for 1 h. Remove an aliquot of the hexane layer and evaporate it to dryness, reconstitute the residue in 1 mL 100 mM HCl, extract with 5 mL chloroform by vortexing for 1 min, centrifuge. Remove a 4.5 mL aliquot of the chloroform layer, evaporate to dryness, dissolve in 10 µL mobile phase, inject an aliquot.

HPLC VARIABLES

Column: 10 µm Micropak CN

Mobile phase: MeCN:5 mM ammonium acetate 90:10 (vary ammonium acetate concentration to achieve best separation)

Flow rate: 2.5

Injection volume: 10-50

Detector: UV 254 or E, Bioanalytical Systems LC-4A, glassy carbon electrode +0.9 V, Ag/AgCl reference electrode

CHROMATOGRAM

Retention time: 17.0

Limit of detection: 0.1 ng/mL (E), 10 ng/mL (UV)

OTHER SUBSTANCES

Extracted: acetophenazine, amitriptyline, benztrapine, butaperazine, carphenazine, chlorpromazine, fluphenazine, haloperidol, imipramine, mesoridazine, nortriptyline, piperacetazine, orphenadrine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, triflupromazine, trihexyphenidyl

KEY WORDS

plasma; whole blood

REFERENCE

Curry, S.H.; Brown, E.A.; Hu, O.Y.-P.; Perrin, J.H. Liquid chromatographic assay of phenothiazine, thioxanthene and butyrophenone neuroleptics and antihistamines in blood and plasma with conventional and radial compression columns and UV and electrochemical detection, *J.Chromatogr.*, **1982**, 231, 361-376.

SAMPLE

Matrix: blood

Sample preparation: 2 mL Plasma + 1 mL 100 ng/mL prochlorperazine in water + 500 µL saturated sodium carbonate solution, vortex for 5 s, add 5 mL pentane:isopropanol 97:3, shake for 15 min, centrifuge at 1725 g for 10 min, repeat the extraction. Combine the organic layers and evaporate them to dryness at 65°, reconstitute the residue in 200 µL MeCN, inject a 100 µL aliquot.

HPLC VARIABLES

Column: 250 × 4.6 5 µm Zorbax CN

Mobile phase: MeCN:100 mM ammonium acetate buffer 90:10

Flow rate: 4

Injection volume: 100

Detector: E, Bioanalytical Systems, +0.9 V

CHROMATOGRAM

Retention time: 2.74

Internal standard: prochlorperazine (5.56)

Limit of detection: 0.125 ng/mL

Limit of quantitation: 0.25 ng/mL

KEY WORDS

plasma; pharmacokinetics

REFERENCE

McKay,G.; Cooper,J.K.; Midha,K.K.; Hall,K.; Hawes,E.M. Simple and sensitive high-performance liquid chromatographic procedure with electrochemical detection for the determination of plasma concentrations of trimeprazine following single oral doses, *J.Chromatogr.*, **1982**, 233, 417-422.

SAMPLE

Matrix: blood

Sample preparation: 10 mL Whole blood + 1 mL 1 M NaOH + 10 mL hexanes, extract for 30 min, repeat extraction. Combine the organic layers and evaporate them to dryness, reconstitute the residue in 1 mL 100 mM HCl, add 5 mL chloroform, shake gently for 10 min or vortex for 1 min, centrifuge. Remove 4.5 mL of the organic layer and evaporate it to dryness under a stream of nitrogen at 30°, reconstitute the residue in 10 µL mobile phase, inject an aliquot (*J. Chromatogr.* 1982, 231, 361).

HPLC VARIABLES

Column: 10 µm Micropak CN

Mobile phase: MeCN:100 mM ammonium acetate 90:10

Flow rate: 2

Detector: E, Bioanalytical Systems LC-4A, glassy carbon electrode +0.9 V, Ag/AgCl reference electrode

CHROMATOGRAM

Retention time: 4.4

Internal standard: imipramine (6.8)

Limit of quantitation: 0.5 ng/mL

OTHER SUBSTANCES

Extracted: amitriptyline, butaperazine, chlorpromazine, fluphenazine, promazine, thioridazine, trifluoperazine

Simultaneous: acetophenazine, benztropine, carphenazine, haloperidol, imipramine, mesoridazine, nortriptyline, orphenadrine, piperacetazine, thiothixene

Interfering: promethazine, triflupromazine, trihexyphenidyl

KEY WORDS

whole blood

REFERENCE

Hu,O.Y.; Gfeller,E.; Perrin,J.H.; Curry,S.H. Relative bioavailability of trimeprazine tablets investigated in man using HPLC with electrochemical detection, *J.Pharm.Pharmacol.*, **1986**, 38, 172-176.

SAMPLE

Matrix: blood

Sample preparation: 2 mL Whole blood + 5 mL chloroform:isopropanol:n-heptane 60:14:26 + 1.5 mL saturated ammonium chloride solution (pH 9.5), agitate horizontally for 10 min, centrifuge at 2800 g for 10 min. Remove the lower organic layer and evaporate it to dryness under reduced pressure at 45°, reconstitute the residue in 100 µL mobile phase, inject a 50 µL aliquot.

HPLC VARIABLES

Column: 300 × 3.9 4 µm NovaPak C18

Mobile phase: MeOH:THF:10 mM pH 2.6 KH₂PO₄ 65:5:30

Column temperature: 30

Flow rate: 0.8

Injection volume: 50

Detector: UV 250

CHROMATOGRAM

Retention time: 5.87

Limit of detection: 60 ng/mL

OTHER SUBSTANCES

Extracted: metabolites

KEY WORDS

whole blood

REFERENCE

Kintz,P.; Berthault,F.; Tracqui,A.; Mangin,P. A fatal case of alimemazine poisoning, *J.Anal.Toxicol.*, **1995**, *19*, 591-594.

SAMPLE

Matrix: blood

Sample preparation: 2 mL Whole blood or plasma + 2 mL buffer + 5 mL chloroform:isopropanol: n-heptane 60:14:26, shake gently horizontally for 10 min, centrifuge at 2800 g for 10 min. Remove the lower organic layer and evaporate it to dryness under vacuum at 45°, reconstitute the residue in 100 µL mobile phase, centrifuge at 2800 g for 5 min, inject a 50 µL aliquot of the supernatant. (Buffer was saturated ammonium chloride solution 25% diluted with water, adjusted to pH 9.5 with 25% ammonia solution.)

HPLC VARIABLES

Column: 300 × 3.9 4 µm NovaPack C18

Mobile phase: MeOH:THF:buffer 65:5:30 (Buffer was 0.68 g/L (10 mM (sic)) KH₂PO₄ adjusted to pH 2.6 with concentrated orthophosphoric acid.) (At the end of each session wash the column with water for 1 h and MeOH for 1 h, re-equilibrate for 30 min.)

Column temperature: 30

Flow rate: 0.8

Injection volume: 50

Detector: UV 255

CHROMATOGRAM

Retention time: 8.35

Limit of detection: <120 ng/mL

KEY WORDS

whole blood; plasma; interferences may occur—compounds (all of which are extracted) elute in this order tenoxicam; iproniazid; methocarbamol; methotrexate; caffeine; nialamide; colchicine; cytarabine; benzoylecgonine; acetaminophen; diazoxide; dacarbazine; sulfipyrazole; flumazenil; sulpride; morphine; atenolol; toloxatone; terbutaline; albuterol; phenobarbital; ranitidine; tiapride; phenol; chlormezanone; aspirin; metformin; ritodrine; codeine; sultopride; amisulpride; naltrexone; lisinopril; benzocaine; nizatidine; nalorphine; mephenesin; naloxone; sotalol; carteolol; procainamide; carbamazepine; bromazepam; nalbuphine; nadolol; procarbazine; dihydralazine; omeprazole; strychnine; acebutolol; glutethimide; chlorpropamide; glipizide; triazolam; prazosin; flunitrazepam; clonazepam; metoclopramide; melphalan; estazolam; tolbutamide; ephedrine; clonidine; pindolol; clobazam; minoxidil; disopyramide; nitrazepam; dextromethorphan; tofisopam; zopiclone; debrisoquine; sulindac; alprazolam; cycloguanil; lorazepam; methaqualone; ketamine; piroxicam; metoprolol; nifedipine; quinine; mephentermine; prilocaine; pentazocine; oxazepam; tiaprofenic acid; quinidine; celiprolol; ajmaline; yohimbine; lidocaine; secobarbital; viloxazine; mepivacaine; meperidine; doxylamine; labetalol; temazepam; amodiaquine; benperidol; droperidol; hydroxychloroquine; zolpidem; ketoprofen; alminoprofen; cicletanine; moclobemide; chloroquine; cocaine; timolol; nomifensine; ticlopidine; acenocoumarol; vandesine; mexiletine; dipyrindamole; trazodone; pipamperone; pyrimethamine; benzepiril; vincristine; metapramine; chlordiasepoxide; oxprenolol; warfarin; clorazepate; flecainide; phencyclidine; thiopental; fenfluramine; metipranolol; triprolidine; naproxen; buprenorphine; verapamil; buspirone; tianeptine; midazolam; bupivacaine; carbinoxamine; loprazolam; cetirizine; chlorpheniramine; moperone; cibenzoline; medifoxamine; astemizole; vinblastine; nicardipine; bisoprolol; diltiazem; glibornuride; reserpine; aconitine; nitrendipine; diazepam; mianserin; ramipril; haloperidol; tetracaine; alprenolol; aceprometazine; glibenclamide; chlorophenacinone; doxepin; nimodipine; diphenhydramine; cyclizine; histapyrodine; phenylbutazone; demexiptiline; clozapine; proguanil; trifluoperidol; medazepam; cyamemazine; bumadizone; suriclone; propranolol; acepromazine; dothiepin; dextromoramide; fenopropfen; dextropropoxyphene; loxapine; betaxolol; propafenone; promethazine; thioproperazine; methadone; amoxapine; quinupramine; opipramol; cyproheptadine; brompheniramine; mefenidramine; protriptyline; flurbiprofen; tetrazepam; zorubicin; prazepam; alimemazine; loperamide; imipramine; desipramine; levomepromazine; hydroxyzine; niflumic acid; penbutolol; flvoxamine; pimozide; daunorubicin; indomethacin; maprotiline; tropatenine; etodolac; fluoxetine; amitriptyline; nortriptyline; tiocloamarol; diclofenac; mefloquine; trimipramine; chlorambucil;

lidoflazine; ibuprofen; floctafenine; alpidem; loratadine; chlorpromazine; clomipramine; carpi-pramine; thioridazine; fentiazac; clemastine; mefenamic acid; fluphenazine; prochlorperazine; penfluridol; bepridil; terfenadine; trifluoperazine

REFERENCE

Tracqui,A.; Kintz,P.; Mangin,P. Systematic toxicological analysis using HPLC/DAD, *J.Forensic Sci.*, **1995**, *40*, 254-262.

SAMPLE

Matrix: blood, CSF

Sample preparation: 200 μ L Serum, plasma, or CSF + 300 μ L reagent. Flush column A to waste with 500 μ L 500 mM ammonium sulfate, inject sample onto column A, flush column A to waste with 500 μ L 500 mM ammonium sulfate, elute the contents of column A onto column B with mobile phase, monitor the effluent from column B. (Reagent was 8.05 M guanidine hydrochloride and 1.02 M ammonium sulfate in water.)

HPLC VARIABLES

Column: A 30 \times 2.1 40 μ m preparative grade C18 (Analytichem); B 250 \times 4.6 10 μ m Partisil C8

Mobile phase: Gradient. A was 50 mM pH 4.5 KH_2PO_4 . B was MeCN:isopropanol 80:20. A:B 90:10 for 1 min, to 30:70 over 15 min, maintain at 30:70 for 4 min.

Column temperature: 50

Flow rate: 1.5

Detector: UV 280 for 5 min then UV 254

CHROMATOGRAM

Retention time: 7.53

Internal standard: heptanophenone (19.2)

OTHER SUBSTANCES

Extracted: acetazolamide, ampicillin, bromazepam, caffeine, carbamazepine, chloramphenicol, chlorothiazide, diazepam, droperidol, ethionamide, furosemide, isoniazid, methadone, penicillin G, phenobarbital, phenytoin, prazepam, propoxyphene, pyrazinamide, rifampin, trimethoprim

KEY WORDS

plasma; serum; column-switching

REFERENCE

Seifart,H.I.; Kruger,P.B.; Parkin,D.P.; van Jaarsveld,P.P.; Donald,P.R. Therapeutic monitoring of antituberculosis drugs by direct in-line extraction on a high-performance liquid chromatography system, *J.Chromatogr.*, **1993**, *619*, 285-290.

SAMPLE

Matrix: blood, urine

Sample preparation: Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 μ L MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) μ L aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200-350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

HPLC VARIABLES

Guard column: 20 mm long Symmetry C18

Column: 250 \times 4.6 5 μ m Symmetry C8 (Waters)

Mobile phase: Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

Column temperature: 30

Flow rate: 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

Injection volume: 10-30

Detector: UV 253.5

CHROMATOGRAM

Retention time: 15.257

KEY WORDS

whole blood

REFERENCE

Gaillard, Y.; Pépin, G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J. Chromatogr. A*, **1997**, 763, 149-163.

SAMPLE

Matrix: solutions

Sample preparation: Prepare a solution in mobile phase, inject 75-100 μ L aliquot.

HPLC VARIABLES

Column: 250 \times 4.6 5 μ m Supelco

Mobile phase: EtOH:MeCN:t-butylamine 98:2:0.05 (Prepared from 1 gal EtOH + 77 mL MeCN + 1.9 mL t-butylamine.)

Flow rate: 2

Injection volume: 75-100

Detector: UV 254

CHROMATOGRAM

Retention time: 2.6

Internal standard: promazine (5.2)

OTHER SUBSTANCES

Simultaneous: N-acetylprocainamide, amitriptyline, amoxapine, amphetamine, buprion, chlor-diazepoxide, chlorimipramine, chlorpheniramine, chlorpromazine, cocaine, codeine, demoxepam, desipramine, desmethylchloridiazepoxide, desmethyldisopyramide, desmethyldoxepin, dextropropoxyphene, diazepam, disopyramide, doxepin, fluphenazine, hydroxyamoxapine (7- and 8-), 2-hydroxydesipramine, 2-hydroxyimipramine, 10-hydroxynortriptyline, iminostilbene, imipramine, iprindole, maprotiline, meperidine, methadone, morphine, nortriptyline, norzimeidine, oxapam, oxaprotiline, perphenazine, phentermine, procainamide, prochlorperazine, prolixin, promethazine, propoxyphene, protriptyline, pyrilamine, quinidine, thioridazine, trifluoperazine, triflupromazine, trimipramine, zimeldine

Noninterfering: thiopropazine

Interfering: loxepin, mianserin

KEY WORDS

normal phase

REFERENCE

Beierle, F.A.; Hubbard, R.W. Liquid chromatographic separation of antidepressant drugs: I. Tricyclics, *Ther. Drug Monit.*, **1983**, 5, 279-292.

SAMPLE

Matrix: solutions

Sample preparation: Prepare a 10 μ g/mL solution in MeOH, inject a 20 μ L aliquot.

HPLC VARIABLES

Column: 125 \times 4.9 Spherisorb S5W silica

Mobile phase: MeOH containing 10 mM ammonium perchlorate and 1 mL/L 100 mM NaOH in MeOH, pH 6.7

Flow rate: 2

Injection volume: 20

Detector: E, LeCarbone, V25 glassy carbon electrode, + 1.2 V

CHROMATOGRAM

Retention time: 3.7

OTHER SUBSTANCES

Also analyzed: acebutolol, acepromazine, acetophenazine, N-acetylprocainamide, albuterol, alprenolol, amethocaine, amiodarone, amitriptyline, antazoline, atenolol, azacyclonal, bamethan, benactyzine, benperidol, benzethidine, benzocaine, benzoctamine, benzphetamine, benzquinamide, bromhexine, bromodiphenhydramine, bromperidol, brompheniramine, brompromazine, buclizine, bufotenine, bupivacaine, buprenorphine, butacaine, butethamate, chlorcyclizine, chlorpheniramine, chlorphenoxamine, chlorprenaline, chlorpromazine, chlorprothixene, cimetidine, cinchonidine, cinnarizine, clemastine, clomipramine, clonidine, cocaine, cyclazocine, cyclizine, cyclopentamine, cyproheptadine, deserpidine, desipramine, dextromoramide, dextropropoxyphene, dicyclomine, diethylcarbamazepine, diethylpropion, diethylthiambutene, dihydroergotamine, dimethindene, dimethothiazine, diphenhydramine, diphenoxylate, dipiprone, diprenorphine, dipyrindamole, disopyramide, dothiepin, doxapram, doxepin, doxylamine, droperidol, ephedrine, ergocornine, ergocristine, ergocristinine, ergocryptine, ergometrine, ergosine, ergosinine, ergotamine, ethopropazine, etorphine, naphazoline, fenethazine, fenfluramine, fenoterol, fentanyl, flavoxate, fluopromazine, flupenthixol, fluphenazine, flurazepam, haloperidol, hydroxyzine, hyoscine, ibogaine, imipramine, indapamine, iprindole, isothipendyl, isoxsuprine, ketanserine, laudanosine, lidocaine, lofepramine, loxapine, maprotiline, mecamlamine, meclophenoxate, meclozine, medazepam, mephentermine, mepivacaine, meptazinol, mepyramine, mesoridazine, metaraminol, methadone, methamphetamine, methapyrilene, methdilazene, methotrimeprazine, methoxamine, methoxyphenamine, methoxypromazine, methylephedrine, methylergonovine, methysergide, metoclopramide, metopimazine, metoprolol, mianserin, morazone, nadolol, nalorphine, naloxone, naphazoline, nicotine, nifedipine, nomifensine, nortriptyline, noscapine, orphenadrine, oxeladin, oxprenolol, oxymetazolin, papaverine, pargyline, pecazine, penbutolol, pentazocine, penthienate, pericyazine, perphenazine, phenadoxone, phenampromide, phenazocine, phenbutrazate, phendimetrazine, phenelzine, phenylglutarimide, phenindamine, pheniramine, phenmetrazine, phenomorphan, phenoperidine, phenothiazine, phenoxybenzamine, phentolamine, phenylephrine, phenyltoloxamine, physostigmine, piminodine, pimozide, pindolol, pipamazine, pipazethate, piperacetazine, piperidolate, pipradol, pirenzepine, piritramide, pizotifen, practolol, pramoxine, prazosin, prenylamine, prilocaine, primaquine, proadifen, procainamide, procaine, prochlorperazine, procyclidine, proheptazine, prolintane, promazine, promethazine, pronethalol, properidine, propiomazine, propranolol, prothipendyl, protriptyline, proxymetacaine, pseudoephedrine, pyrimethamine, quinidine, quinine, ranitidine, rescinnamine, sotalol, tacrine, terazosin, terbutaline, terfenadine, thenyldiamine, theophylline, thiethylperazine, thiopropazate, thiopropazine, thioridazine, thiothixene, thonzylamine, timolol, tocinide, tolpropamine, tolycaine, tranlylcypromine, trazodone, trifluoperazine, trifluoperidol, trimeperidine, trimethobenzamide, trimethoprim, trimipramine, tripelethamine, triprolidine, tryptamine, verapamil, xylometazoline

REFERENCE

Jane, L.; McKinnon, A.; Flanagan, R.J. High-performance liquid chromatographic analysis of basic drugs on silica columns using non-aqueous ionic eluents. II. Application of UV, fluorescence and electrochemical oxidation detection, *J. Chromatogr.*, **1985**, *323*, 191-225.

SAMPLE

Matrix: solutions

Sample preparation: Dissolve in MeOH:water 1:1 at a concentration of 50 µg/mL, inject a 10 µL aliquot.

HPLC VARIABLES

Column: 300 × 3.9 10 µm µBondapak C18

Mobile phase: MeOH:acetic acid:triethylamine:water 60:1.5:0.5:38

Flow rate: 1.5

Injection volume: 10

Detector: UV

CHROMATOGRAM

Retention time: k' 2.07

REFERENCE

Roos,R.W.; Lau-Cam,C.A. General reversed-phase high-performance liquid chromatographic method for the separation of drugs using triethylamine as a competing base, *J.Chromatogr.*, **1986**, 370, 403-418.

SAMPLE

Matrix: solutions

Sample preparation: Prepare a solution in mobile phase, inject a 40 μ L aliquot.

HPLC VARIABLES

Guard column: Pelliguard LC-CN (Supelco)

Column: 150 \times 4.6 5 μ m Supelcosil LC-PCN

Mobile phase: MeCN:MeOH:10 mM pH 7.0 phosphate buffer 58:14:28

Flow rate: 1.2

Injection volume: 40

Detector: UV 254

CHROMATOGRAM

Retention time: 5.8

OTHER SUBSTANCES

Simultaneous: amitriptyline, atropine, butalbital, chlorpromazine, desipramine, desmethylmaprotiline, doxepin, imipramine, maprotiline, methadone, norpropoxyphene, nortriptyline, phenylpropanolamine, procainamide, prochlorperazine, promethazine, propranolol, protriptyline, trimipramine

Noninterfering: acetaminophen, allopurinol, amikacin, amoxapine, amytal, bretylium, caffeine, carbamazepine, carisoprodol, chloramphenicol, chlordiazepoxide, chlorpropamide, clonazepam, codeine, diazepam, disopyramide, droperidol, ethinamate, ethinamate, ethosuximide, fluphenazine, flurazepam, furosemide, gentamicin, haloperidol, hydrochlorothiazide, hydroxyzine, ibuprofen, kanamycin, lidocaine, loxapine, meperidine, mephobarbital, meprobamate, methaqualone, methotrexate, morphine, nafcillin, naloxone, neomycin, perphenazine, phenacetin, phenobarbital, phenytoin, prazepam, primidone, procaine, propoxyphene, reserpine, salicylamide, salicylic acid, secobarbital, spironolactone, theophylline, thiopental, thioridazine, tobramycin, valproic acid, verapamil

Interfering: N-propionylprocainamide, quinidine, trifluoperazine

REFERENCE

Lin,W.-N.; Frade,P.D. Simultaneous quantitation of eight tricyclic antidepressants in serum by high-performance liquid chromatography, *Ther.Drug Monit.*, **1987**, 9, 448-455.

SAMPLE

Matrix: solutions

Sample preparation: Inject a 50 μ L aliquot of a 20 mg/mL solution. Collect eluted enantiomers by switching column effluent onto one of two 100 \times 4.6 25-40 μ m Lichroprep RP18 columns. Wash these columns with 2.5 mL water, wash with 5 mL MeCN:water 10:90, elute with MeCN: 0.14% trifluoroacetic acid in water 70:30, evaporate eluate to give the enantiomers as their trifluoroacetate salts.)

HPLC VARIABLES

Column: 100 \times 4 5 μ m SGE-100GLC4-C8-30/5 octylsilica (Scientific Glass Engineering)

Mobile phase: MeCN:buffer 10:90 containing 9 g/L β -cyclodextrin (Buffer was 0.8% triethylamine adjusted to pH 4 with glacial acetic acid.)

Injection volume: 50

Detector: UV

CHROMATOGRAM

Retention time: 8.5, 10 (enantiomers)

KEY WORDS

chiral; preparative

REFERENCE

Cooper, A.D.; Jefferies, T.M. On-line recovery of trimeprazine enantiomers following chiral separation by reversed-phase high-performance liquid chromatography using a β -cyclodextrin-containing mobile phase, *J.Pharm.Biomed.Anal.*, **1990**, 8, 847–851.

SAMPLE

Matrix: solutions

HPLC VARIABLES

Column: 250 \times 4.6 5 μ m Supelcosil LC-DP (A) or 250 \times 4 5 μ m LiChrospher 100 RP-8 (B)

Mobile phase: MeCN:0.025% phosphoric acid:buffer 25:10:5 (A) or 60:25:15 (B) (Buffer was 9 mL concentrated phosphoric acid and 10 mL triethylamine in 900 mL water, adjust pH to 3.4 with dilute phosphoric acid, make up to 1 L.)

Flow rate: 0.6

Injection volume: 25

Detector: UV 229

CHROMATOGRAM

Retention time: 14.91 (A), 7.07 (B)

OTHER SUBSTANCES

Also analyzed: acebutolol, acepromazine, acetaminophen, acetazolamide, acetophenazine, albuterol, alprazolam, amitriptyline, amobarbital, amoxapine, antipyrine, atenolol, atropine, azatadine, baclofen, benzocaine, bromocriptine, brompheniramine, brotizolam, bupivacaine, buspirone, butabarbital, butalbital, caffeine, carbamazepine, cetirizine, chlorcyclizine, chlordiazepoxide, chlormezanone, chloroquine, chlorpheniramine, chlorpromazine, chlorpropamide, chlorprothixene, chlorthalidone, chlorzoxazone, cimetidine, cisapride, clomipramine, clonazepam, clonidine, clozapine, cocaine, codeine, colchicine, cyclizine, cyclobenzaprine, dantrolene, desipramine, diazepam, diclofenac, diflunisal, diltiazem, diphenhydramine, diphenidol, diphenoxylate, dipyrindamole, disopyramide, dobutamine, doxapram, doxepin, droperidol, encainide, ethidium bromide, ethopropazine, fenoprofen, fentanyl, flavoxate, fluoxetine, fluphenazine, flurazepam, flurbiprofen, fluvoxamine, furosemide, glutethimide, glyburide, guaifenesin, haloperidol, homatropine, hydralazine, hydrochlorothiazide, hydrocodone, hydromorphone, hydroxychloroquine, hydroxyzine, ibuprofen, imipramine, indomethacin, ketoconazole, ketoprofen, ketorolac, labetalol, levorphanol, lidocaine, loratadine, lorazepam, lovastatin, loxapine, mazinol, mefenamic acid, meperidine, mephénytoin, mepivacaine, mesoridazine, metaproterenol, metformin, methadone, methdilazine, methocarbamol, methotrexate, methotrimprazine, methoxamine, methyl dopa, methylphenidate, metoclopramide, metolazone, metoprolol, metronidazole, midazolam, moclobemide, morphine, nadolol, nalbuphine, naloxone, naphazoline, naproxen, nifedipine, nizatidine, norepinephrine, nortriptyline, oxazepam, oxycodone, oxymentazoline, paroxetine, pemoline, pentazocine, pentobarbital, pentoxifylline, perphenazine, pheniramine, phenobarbital, phenol, phenolphthalein, phenolamine, phenylbutazone, phenyltoloxamine, phenytion, pimizole, pindolol, piroxicam, pramoxine, prazepam, prazosin, probenecid, procainamide, procaine, prochlorperazine, procyclidine, promazine, promethazine, propafenone, propantheline, propiomazine, propofol, propranolol, protriptyline, quazepam, quinidine, quinine, racemethorphan, ranitidine, remoxipride, risperidone, salicylic acid, scopolamine, secobarbital, sertraline, sotalol, spironolactone, sulfipyrazone, sulindac, temazepam, terbutaline, terfenadine, tetracaine, theophylline, thiethylperazine, thiopental, thioridazine, thiothixene, timolol, tocainide, tolbutamide, tolmetin, trazodone, triamterene, triazolam, trifluoperazine, trifluopromazine, trimethoprim, trimipramine, verapamil, warfarin, xylometazoline, yohimbine, zopiclone

KEY WORDS

details of plasma extraction

REFERENCE

Koves, E.M. Use of high-performance liquid chromatography-diode array detection in forensic toxicology, *J.Chromatogr.A*, **1995**, 692, 103–119.

SAMPLE

Matrix: solutions

Sample preparation: Make up a 500 ng/mL solution in mobile phase, inject an aliquot.

HPLC VARIABLES

Column: 250 × 4.6 5 µm Sumchiral OA-4700 (S)-tert-leucine-(R)-1-(α-naphthyl)ethylamine (YMC)

Mobile phase: Hexane:1,2-dichloroethane:EtOH:trifluoroacetic acid 800:150:100:1

Flow rate: 1

Injection volume: 100

Detector: F ex 254 em 280 (filter)

CHROMATOGRAM

Retention time: 5.73, 6.26 (enantiomers)


KEY WORDS

chiral

REFERENCE

Ponder, G.W.; Butram, S.L.; Adams, A.G.; Ramanathan, C.S.; Stewart, J.T. Resolution of promethazine, ethopropazine, trimeprazine and trimipramine enantiomers on selected chiral stationary phases using high-performance liquid chromatography, *J.Chromatogr.A*, **1995**, 692, 173–182.

Trimetazidine



Molecular formula: C₁₄H₂₂N₂O₃

Molecular weight: 266.34

CAS Registry No.: 5011-34-7, 13171-25-0 (2.HCl)

Merck Index: 9835

SAMPLE

Matrix: blood, urine

Sample preparation: Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 µL MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) µL aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200–350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

HPLC VARIABLES

Guard column: 20 mm long Symmetry C18

Column: 250 × 4.6 5 µm Symmetry C8 (Waters)

Mobile phase: Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

Column temperature: 30

Flow rate: 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

Injection volume: 10–30

Detector: UV 206.4

CHROMATOGRAM

Retention time: 6.06


KEY WORDS

whole blood

REFERENCE

Gaillard, Y.; Pépin, G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J.Chromatogr.A*, **1997**, 763, 149–163.

Trimethadione



Molecular formula: $C_6H_9NO_3$

Molecular weight: 143.14

CAS Registry No.: 127-48-0

Merck Index: 9836

Lednicer No.: 1 232

SAMPLE

Matrix: blood

Sample preparation: 50 μ L Serum + 50 μ L α -methyl- α -propylsuccinimide in MeOH, shake for 2 min, centrifuge at 1500 g for 5 min, inject a 10-20 μ L aliquot of the supernatant.

HPLC VARIABLES

Column: 150 \times 4.6 5 μ m Shodex ODSpak F-411A

Mobile phase: MeCN:water:PIC-B5 (low UV) 15:85:3.5

Injection volume: 10-20

Detector: UV 200

CHROMATOGRAM

Retention time: 5.5

Internal standard: α -methyl- α -propylsuccinimide (12.7)

Limit of quantitation: 100 ng/mL

OTHER SUBSTANCES

Extracted: metabolites

Noninterfering: acetazolamide, carbamazepine, pentobarbital, phenobarbital, phenytoin, primidone


KEY WORDS

serum; rat; human; pharmacokinetics

REFERENCE

Tanaka, E.; Hagino, S.; Yoshida, T.; Kuroiwa, Y. Simultaneous determination of trimethadione and its metabolite in rat and human serum by high-performance liquid chromatography, *J. Chromatogr.*, **1984**, *308*, 393-397.

Trimethobenzamide



Molecular formula: $C_{21}H_{28}N_2O_5$

Molecular weight: 388.46

CAS Registry No.: 138-56-7, 554-92-7 (HCl)

Merck Index: 9839

Lednicer No.: 1 110

SAMPLE

Matrix: blood

Sample preparation: 2 mL Serum or plasma + 100 μ L 10 μ g/mL trimethobenzamide in MeOH + 1 mL buffer + 10 mL n-butyl chloride:isopropanol 95:5, shake for 10 min, centrifuge at 500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of air at 40°, reconstitute the residue in 200 μ L chloroform and 200 μ L 25 mM HCl, vortex for 10 s, centrifuge at 500 g for 3-5 min, inject a 50-60 μ L aliquot of the upper aqueous layer. (Buffer was 630 mL of a solution containing 1 M boric acid and 1 M KCl + 370 mL 1 M sodium carbonate, adjust pH to 9.0.)

HPLC VARIABLES

Column: 250 × 4.6 5 µm cyanopropyltrimethylsilyl (PCN) (Supelco)

Mobile phase: MeCN:0.06% phosphoric acid 15:85 containing 0.01% octylamine (After analysis wash out system with MeCN:water 20:80.)

Flow rate: 2

Injection volume: 50-60

Detector: UV 254

CHROMATOGRAM

Retention time: 5.5

Internal standard: trimethobenzamide

OTHER SUBSTANCES

Extracted: encainide

Simultaneous: dipyridamole, oxazepam

Noninterfering: amiodarone, caffeine, chloral hydrate, chlordiazepoxide, diazepam, ethosuximide, flecainide, lidocaine, methadone, mexiletine, nicotine, phenobarbital, phenytoin, primidone, procainamide, propranolol, quinidine, tocainide, tricyclic antidepressants

KEY WORDS

plasma; serum; trimethobenzamide is IS

REFERENCE

Dasgupta, A.; Rosenzweig, I.B.; Turgeon, J.; Raisys, V.A. Encainide and metabolites analysis in serum or plasma using a reversed-phase high-performance liquid chromatographic technique, *J. Chromatogr.*, **1990**, 526, 260-265.

SAMPLE

Matrix: solutions

Sample preparation: Prepare a 10 µg/mL solution in MeOH, inject a 20 µL aliquot.

HPLC VARIABLES

Column: 125 × 4.9 Spherisorb S5W silica

Mobile phase: MeOH containing 10 mM ammonium perchlorate and 1 mL/L 100 mM NaOH in MeOH, pH 6.7

Flow rate: 2

Injection volume: 20

Detector: E, LeCarbone, V25 glassy carbon electrode, + 1.2 V

CHROMATOGRAM

Retention time: 4.9

OTHER SUBSTANCES

Also analyzed: acebutolol, acepromazine, acetophenazine, N-acetylprocainamide, albuterol, alprenolol, amethocaine, amiodarone, amitriptyline, antazoline, atenolol, azacyclonal, bamethan, benactyzine, benperidol, benzethidine, benzocaine, benzocetamine, benzphetamine, benzquinamide, bromhexine, bromodiphenhydramine, bromperidol, brompheniramine, brompromazine, buclizine, bufotenine, bupivacaine, buprenorphine, butacaine, butethamate, chlorcyclizine, chlorpheniramine, chlorphenoxamine, chlorprenaline, chlorpromazine, chlorprothixene, cimetidine, cinchonidine, cinnarizine, clemastine, clomipramine, clonidine, cocaine, cyclazocine, cyclozine, cyclopentamine, cyproheptadine, deserpidine, desipramine, dextromoramide, dextropropoxyphene, dicyclomine, diethylcarbamazine, diethylpropion, diethylthiambutene, dihydroergotamine, dimethindene, dimethothiazine, diphenhydramine, diphenoxylate, dipiprone, diprenorphine, dipyridamole, disopyramide, dothiepin, doxapram, doxepin, doxylamine, droperidol, ephedrine, ergocornine, ergocristine, ergocristinine, ergocryptine, ergometrine, ergosine, ergosinine, ergotamine, ethopropazine, etorphine, etoxeridine, fenethazine, fenfluramine, fenoterol, fentanyl, flavoxate, fluopromazine, flupenthixol, fluphenazine, flurazepam, haloperidol, hydroxyzine, hyoscine, ibogaine, imipramine, indapamine, iprindole, isothipendyl, isoxsuprine, ketanserine, laudanosine, lidocaine, lofepramine, loxapine, maprotiline, mecamylamine, meclorphenoxate, meclozine, medazepam, mephentermine, mepivacaine, meptazinol, mepyramine, mesoridazine, metaraminol, methadone, methamphetamine, methapyrilene, methdilazene, methotrimeprazine, methoxamine, methoxyphenamine, methoxypromazine,

methylephedrine, methylegonovine, methysergide, metoclopramide, metopimazine, metoprolol, mianserin, morazone, nadolol, nalorphine, naloxone, naphazoline, nicotine, nifedipine, nomifensine, nortriptyline, noscapine, orphenadrine, oxeladin, oxprenolol, oxymetazolin, papaverine, pargyline, pecazine, penbutolol, pentazocine, penthienate, pericyazine, perphenazine, phenadoxone, phenampromide, phenazocine, phenbutrazate, phendimetrazine, phenelzine, phenglutarimide, phenindamine, pheniramine, phenmetrazine, phenomorphan, phenoperidine, phenothiazine, phenoxybenzamine, phentolamine, phenylephrine, phenyltoloxamine, physostigmine, piminodine, pimozide, pindolol, pipamazine, pipazethate, piperacetazine, piperidolate, pipradol, pirenzepine, piritramide, pizotifen, practolol, pramoxine, prazosin, prenylamine, prilocaine, primaquine, proadifen, procainamide, procaine, prochlorperazine, procyclidine, proheptazine, prolintane, promazine, promethazine, pronethalol, properidine, propiomazine, propranolol, prothipendyl, protriptyline, proxymetacaine, pseudoephedrine, pyrimethamine, quinidine, quinine, ranitidine, rescinnamine, sotalol, tacrine, terazosin, terbutaline, terfenadine, thenyldiamine, theophylline, thiethylperazine, thiopropazate, thioproperazine, thioridazine, thiothixene, thonzylamine, timolol, tocinide, tolpropamine, tolycaine, tranlycypromine, trazodone, trifluoperazine, trifluoperidol, trimeperidine, trimeprazine, trimethoprim, trimipramine, tripeleennamine, triprolidine, tryptamine, verapamil, xylometazoline

REFERENCE

Jane, I.; McKinnon, A.; Flanagan, R. J. High-performance liquid chromatographic analysis of basic drugs on silica columns using non-aqueous ionic eluents. II. Application of UV, fluorescence and electrochemical oxidation detection, *J. Chromatogr.*, **1985**, 323, 191–225.

Trimethoprim


Molecular formula: C₁₄H₁₈N₄O₃

Molecular weight: 290.32

CAS Registry No.: 738-70-5

Merck Index: 9840

Lednicer No.: 1 262



SAMPLE

Matrix: blood

Sample preparation: Add 1.5 mL MeCN to 500 µL serum, centrifuge, evaporate the supernatant to dryness, redissolve the residue in 200 µL water. Inject onto column A, wash with MeCN: water 10:90 or MeOH:water 20:80 for 20 min, backflush the contents of column A onto column B with mobile phase, elute with mobile phase, monitor the effluent from column B.

HPLC VARIABLES

Column: A 25 × 4 25 µm pore diameter 6 nm LiChrospher RP-18 ADS (Merck); B 125 × 4 5 µm endcapped LiChroCART HPLC-cartridge RP-18 (Merck)

Mobile phase: MeOH:20 mM pH 4 phosphate buffer 38:62

Column temperature: 30

Flow rate: 1

Injection volume: 200

Detector: UV 245, F ex 270 em 389

CHROMATOGRAM

Retention time: 1.9

OTHER SUBSTANCES

Extracted: triamterene

KEY WORDS

serum; column-switching

REFERENCE

Oertel, R.; Richter, K.; Gramatté, T.; Kirch, W. Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing, *J. Chromatogr. A*, **1998**, 797, 203–209.

SAMPLE

Matrix: blood

Sample preparation: 50 μ L Serum + 75 μ L acetone:10% trichloroacetic acid 1:2, vortex for 5 s, centrifuge for 4 min. Remove 62.5 μ L of the supernatant and add it to 62.5 μ L 50 mM KH_2PO_4 , add 250 μ L diethyl ether, vortex for 10 s, centrifuge for 5 min, filter (0.45 μ m) the lower aqueous layer, inject a 20 μ L aliquot of the filtrate.

HPLC VARIABLES

Column: 75 \times 4.6 TSK gel ODS-80TM (Tosoh)

Mobile phase: MeCN:50 mM pH 6.0 KH_2PO_4 8:92

Flow rate: 1

Injection volume: 20

Detector: UV 235

CHROMATOGRAM

Retention time: 30

Internal standard: trimethoprim

OTHER SUBSTANCES

Extracted: vancomycin

KEY WORDS

serum; trimethoprim is IS

REFERENCE

Morishige,H.; Shuto,H.; Ieiri,I.; Otsubo,K.; Oishi,R. Instability of standard calibrators may be involved in over-estimating vancomycin concentrations determined by fluorescence polarization immunoassay, *Ther.Drug Monit.*, **1996**, 18, 80–85.

SAMPLE

Matrix: blood, urine

Sample preparation: Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 μ L MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) μ L aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200-350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

HPLC VARIABLES

Guard column: 20 mm long Symmetry C18

Column: 250 \times 4.6 5 μ m Symmetry C8 (Waters)

Mobile phase: Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

Column temperature: 30

Flow rate: 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

Injection volume: 10-30

Detector: UV 205.2

CHROMATOGRAM

Retention time: 8.282

KEY WORDS

whole blood

REFERENCE

Gaillard,Y.; Pépin,G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J.Chromatogr.A*, **1997**, 763, 149–163.

SAMPLE**Matrix:** solutions

HPLC VARIABLES**Column:** 300 × 0.35 5 µm Vydac IDI-TP C18 TMS capped**Mobile phase:** Gradient. MeOH:buffer 0:100 at start of run, to 10:90 after injection (step gradient), to 12:88 over 30 min, to 18:82 over 5 min, to 30:70 over 5 min. (Buffer was 1 mM pH 2.72 phosphate buffer)**Column temperature:** 30**Flow rate:** 0.006**Injection volume:** 1**Detector:** UV 270

CHROMATOGRAM**Retention time:** 31

OTHER SUBSTANCES**Simultaneous:** diaveridine, phthalyl sulfathiazole, pyrimethamine, succinyl sulfathiazole, sulfabenzamide, sulfacetamide, sulfachloropyridazine, sulfadiazine, sulfadimethoxine, sulfaguanidine, sulfamerazine, sulfameter, sulfamethazine, sulfamethizole, sulfamethoxazole, sulfamethoxypyridazine, sulfamoxole, sulfanilamide, sulfanilic acid, sulfapyridine, sulfaquinoxaline, sulfathiazole, sulfisomidine, sulfisoxazole

KEY WORDScapillary HPLC

REFERENCERicci, M.C.; Cross, R.F. High-performance liquid chromatographic analyses of sulphonamides and dihydrofolate reductase inhibitors. I. Separations in methanol-modified solutions, *J.Liq.Chromatogr.Rel.Technol.*, **1996**, *19*, 365–381.

SAMPLE**Matrix:** solutions

HPLC VARIABLES**Column:** 300 × 0.35 5 µm Vydac IDI-TP C18 TMS capped**Mobile phase:** Gradient. MeCN:MeOH:buffer 0:0:100 at start of run, to 0:5:95 after injection (step gradient), to 0:8:92 over 7 min, to 6:0:94 (step gradient), maintain at 6:0:94 for 14 min, to 0:16:84 over 5 min, to 0:18:82 over 5 min, to 0:30:70 over 5 min. (Buffer was 1 mM pH 2.72 phosphate buffer.)**Column temperature:** 30**Flow rate:** 0.006**Injection volume:** 1**Detector:** UV 270

CHROMATOGRAM**Retention time:** 27.5

OTHER SUBSTANCES**Simultaneous:** diaveridine, phthalyl sulfathiazole, pyrimethamine, succinyl sulfathiazole, sulfabenzamide, sulfacetamide, sulfachloropyridazine, sulfadiazine, sulfadimethoxine, sulfaguanidine, sulfamerazine, sulfameter, sulfamethazine, sulfamethizole, sulfamethoxazole, sulfamethoxypyridazine, sulfamoxole, sulfanilamide, sulfanilic acid, sulfapyridine, sulfaquinoxaline, sulfathiazole, sulfisomidine, sulfisoxazole

KEY WORDScapillary HPLC

REFERENCERicci, M.C.; Cross, R.F. High performance liquid chromatographic analyses of sulphonamides and dihydrofolate reductase inhibitors. II. Separations in acetonitrile modified solutions, ternary gradient studies & flow programming, *J.Liq.Chromatogr.Rel.Technol.*, **1996**, *19*, 547–564.

Trimetrexate


Molecular formula: $C_{19}H_{23}N_5O_3$

Molecular weight: 369.42

CAS Registry No.: 52128-35-5, 82952-64-5 (glucuronate)

Merck Index: 9851

Lednicer No.: 4 149



SAMPLE

Matrix: blood

Sample preparation: Condition a 100 mg Bond Elut C2 SPE cartridge with two 1 mL portions of MeOH and two 1 mL portions of water, do not allow to go dry. 1 mL Plasma + 160 ng IS, vortex, add to the SPE cartridge at 0.5 mL/min, wash with two 1 mL portions of water, dry under vacuum for 1 min, wash with 250 μ L MeCN, dry under vacuum for 20 s, elute with 500 μ L MeOH:water 95:5. Evaporate the eluate to dryness under a stream of nitrogen at 37°, reconstitute the residue in 400 μ L mobile phase, vortex for 30 s, centrifuge at 1800 g for 15 min, inject a 100 μ L aliquot.

HPLC VARIABLES

Guard column: 30 \times 4.6 7 μ m Zorbax TMS

Column: 250 \times 4.6 5 μ m Zorbax TMS

Mobile phase: MeCN:buffer 23:77 (Buffer was 50 mM $(NH_4)H_2PO_4$ containing 0.8% triethylamine and 0.2% phosphoric acid, pH 4.5.)

Column temperature: 45

Flow rate: 1.2

Injection volume: 100

Detector: UV 241

CHROMATOGRAM

Retention time: 9.4

Internal standard: N6-phenylmethyl-2,4,6-quinazolinetriamine (12.0)

Limit of quantitation: 2.4 ng/mL

OTHER SUBSTANCES

Noninterfering: metabolites, cisplatin, cytarabine, doxorubicin, etoposide, 5-fluorouracil, folinic acid (leucovorin), lomustine, methotrexate, morphine, prednisolone, ribavirin, sulfamethoxazole, 6-thioguanine, trimethoprim, vinblastine, vincristine, zidovudine

Interfering: chlorambucil, melphalan

KEY WORDS

SPE; plasma; pharmacokinetics

REFERENCE

Bullen, W.W.; Chang, T.; Whitfield, L.R. High-performance liquid chromatographic assay for trimetrexate in human plasma, *J. Chromatogr.*, **1990**, 526, 266–272.

SAMPLE

Matrix: blood, feces, urine

Sample preparation: Plasma. Condition a SPICE ODS SPE cartridge (Analtech) with 7.5 mL MeOH and 7.5 mL buffer. 1 mL Plasma + 1 mL buffer, add to SPE cartridge, wash with two 2.5 mL portions of buffer, dry under vacuum, elute with two 2.5 mL portions of MeOH:triethylamine 99:1. Evaporate the eluate to dryness under reduced pressure, reconstitute with 1 mL mobile phase, inject a 200 μ L aliquot. Feces. Condition a SPICE ODS SPE cartridge (Analtech) with 7.5 mL MeOH and 7.5 mL water. Add dithiothreitol to feces (final concentration 1 mM), add an equal volume of water, add to SPE cartridge, wash with two 2.5 mL portions of MeOH:water 12.5:87.5, dry under vacuum, elute with two 2.5 mL portions of MeOH:triethylamine 99:1. Evaporate the eluate to dryness under reduced pressure, reconstitute with 1 mL mobile phase, add dithiothreitol (final concentration 1 mM), inject a 200 μ L aliquot. Urine. Dilute 1:10 to 1:100 with 15 μ M IS in mobile phase, inject an aliquot. (Buffer was 1.5% acetic acid adjusted to pH 5.5 with ammonium hydroxide.)

HPLC VARIABLES**Guard column:** 5 μm ODS (Brownlee)**Column:** 250 \times 4.6 5 μm Ultrasphere ODS**Mobile phase:** MeCN:50 mM NaH_2PO_4 :acetic acid 17:82.2:0.8 adjusted to pH 5.5 with triethylamine**Column temperature:** 20**Flow rate:** 1**Injection volume:** 200**Detector:** E, Bioanalytical Systems LC-4A, 0.6 V or UV 254

CHROMATOGRAM**Retention time:** 40**Internal standard:** N,N-diethyl-5,7-dimethoxytryptamine hydrogen oxalate (35)**Limit of quantitation:** 20 nM (feces), 50 nM (plasma, urine)

KEY WORDSplasma; SPE; pharmacokinetics

REFERENCE

Lin,J.T.; Cashmore,A.R.; Baker,M.; Dreyer,R.N.; Ernstoff,M.; Marsh,J.C.; Bertino,J.R.; Whitfield,L.R.; Delap,R.; Grillo-Lopez,A. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics, *Cancer Res.*, **1987**, 47, 609–616.

SAMPLE**Matrix:** blood, urine

Sample preparation: Condition a 500 mg C18 Bond Elut SPE cartridge with three column volumes of MeOH and three column volumes of water. Plasma, serum. Centrifuge plasma for 3–5 min. Add 1 mL serum or plasma to the SPE cartridge, wash with 6 mL water, wash with 1.5 mL MeCN, wash with 500 μL water, elute with 1 mL MeOH:80 mM sodium citrate 95:5. Filter (0.45 μm) the eluate, inject a 10 μL aliquot of the filtrate. Urine. Add 1 mL urine to the SPE cartridge, wash with 6 mL water, wash with 1 mL MeCN, wash with 1 mL MeOH:20 mM pH 4.5 sodium acetate 25:75, elute with 1.25 mL MeOH:80 mM sodium citrate 95:5. Filter (0.45 μm) the eluate, inject a 10 μL aliquot of the filtrate.

HPLC VARIABLES**Guard column:** 30 \times 4.6 Spherisorb RP-18**Column:** 300 \times 3.9 10 μm Bondapak C18**Mobile phase:** MeCN:Buffer 40:60 (Buffer was water containing 0.02% phosphoric acid and 0.08% triethylamine.)**Flow rate:** 2**Injection volume:** 10**Detector:** UV 241

CHROMATOGRAM**Retention time:** 4.5**Limit of quantitation:** 50 ng/mL (urine), 20 ng/mL (plasma)

OTHER SUBSTANCES**Extracted:** metabolites

KEY WORDSplasma; serum; SPE; human; mouse

REFERENCE

Ackerly,C.C.; Hartshorn,J.; Tong,W.P.; McCormack,J.J. A rapid and sensitive method for determination of trimetrexate from biological fluids, *J.Liq.Chromatogr.*, **1985**, 8, 125–134.

SAMPLE**Matrix:** blood, urine

Sample preparation: Condition a 500 mg C18 Bond Elut SPE cartridge with three column volumes of MeOH and three column volumes of water. Plasma, serum. Centrifuge plasma for

3-5 min. Add 1 mL serum or plasma to the SPE cartridge, wash with 6 mL water, wash with 1.5 mL MeCN, wash with 500 μ L water, elute with 1 mL MeOH:80 mM sodium citrate 95:5. Filter (0.45 μ m) the eluate, inject a 10 μ L aliquot of the filtrate. Urine. Add 1 mL urine to the SPE cartridge, wash with 6 mL water, wash with 1 mL MeCN, wash with 1 mL MeOH:20 mM pH 4.5 sodium acetate 25:75, elute with 1.25 mL MeOH:80 mM sodium citrate 95:5. Filter (0.45 μ m) the eluate, inject a 10 μ L aliquot of the filtrate (J.Liq.Chromatogr. 1985, 8, 125).

HPLC VARIABLES

Guard column: 15 \times 3.2 7 μ m Aquapore C18

Column: 100 \times 4.6 5 μ m Spherisorb ODS

Mobile phase: Gradient. MeCN:buffer from 15:85 to 40:60 over 10 min, re-equilibrate at initial conditions for 10 min. (Buffer was 0.08% triethylamine containing 0.04% phosphoric acid.)

Flow rate: 1.5

Injection volume: 10

Detector: UV 241

CHROMATOGRAM

Retention time: 7.6

Limit of quantitation: 100 ng/mL

KEY WORDS

plasma; serum; SPE

REFERENCE

Hudes,G.R.; LaCreta,F.; DeLap,R.J.; Grillo-Lopez,A.J.; Catalano,R.; Comis,R.L. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil, *Cancer Chemother.Pharmacol.*, **1989**, 24, 117-122.

SAMPLE

Matrix: formulations

Sample preparation: Dilute injection 1:5 with MeOH:water 50:50, inject a 2 μ L aliquot.

HPLC VARIABLES

Column: 100 \times 2 5 μ m MOS C8 (Hewlett-Packard)

Mobile phase: MeCN:MeOH:50 mM $(\text{NH}_4)_2\text{H}_2\text{PO}_4$ 18:12:70

Flow rate: 0.5

Injection volume: 2

Detector: UV 254

CHROMATOGRAM

Retention time: 2.03

OTHER SUBSTANCES

Simultaneous: degradation products

KEY WORDS

injections; water

REFERENCE

Stetson,P.L.; Shukla,U.A.; Ensminger,W.D. Stability of trimetrexate, a new non-classical antifolate, in infusion solutions, *J.Chromatogr.*, **1989**, 464, 163-171.

SAMPLE

Matrix: urine

Sample preparation: Condition a 1 mL 100 mg Bond Elut CN SPE cartridge with 3 mL MeCN and 3 mL water. 1 mL Urine + 100 μ L 20 μ g/mL trimethoprim in water + 1 mL water, add to the SPE cartridge, wash with 3 mL water, elute with 1 mL MeCN:water 15:85 containing 0.75% triethylamine and 0.375% phosphoric acid (85%), inject a 200 μ L aliquot.

HPLC VARIABLES


Guard column: 15 \times 3.2 7 μ m Aquapore C18 (Brownlee)

Column: 100 × 4.6 5 µm Hypersil ODS C18**Mobile phase:** Gradient. MeCN:buffer from 9:91 to 35:65, re-equilibrate at initial conditions for 5 min. Buffer was 0.16% triethylamine containing 0.08% orthophosphoric acid (85%), pH 4.2.)**Flow rate:** 1.5**Injection volume:** 200**Detector:** UV 241**CHROMATOGRAM****Retention time:** 11.0**Internal standard:** trimethoprim (5.8)**Limit of quantitation:** 100 ng/mL**KEY WORDS**

SPE

REFERENCETinsley,P.W.; LaCreta,F.P. Improved chromatographic method for the determination of trimetrexate in urine, *J.Chromatogr.*, **1990**, 529, 468–472.


Trimidox

Molecular formula: C₇H₈N₂O₄**Molecular weight:** 184.15**SAMPLE****Matrix:** bulk**Sample preparation:** Prepare a 0.1 mM solution in 10 mM KH₂PO₄, adjust pH to 6 with a few drops 5 M KOH or phosphoric acid, inject a 20 µL aliquot.**HPLC VARIABLES****Column:** 150 × 4.6 3 µm Supelcosil LC18**Mobile phase:** MeOH:buffer 5:95 (Buffer was 0.05% triethylamine adjusted to pH 6 with 50 mM phosphoric acid.)**Flow rate:** 0.5**Injection volume:** 20**Detector:** UV 255**OTHER SUBSTANCES****Simultaneous:** amidox, didox**KEY WORDS**

comparison with DC polarography and UV spectrophotometry

REFERENCERomanova,D.; Vachalkova,A.; Szekeres,T.; Elford,H.L.; Novotny,L. The new inhibitors of ribonucleotide reductase -comparison of some physico-chemical properties, *J.Pharm.Biomed.Anal.*, **1997**, 15, 951–956.

Trimipramine

Molecular formula: C₂₀H₂₆N₂**Molecular weight:** 294.44**CAS Registry No.:** 739-71-9, 521-78-8 (maleate)**Merck Index:** 9852

SAMPLE**Matrix:** blood**Sample preparation:** Condition a 15 mg 3 mL PLUS.MPI (Ansys, USA) SPE disc with 200 μ L MeOH and 200 μ L 100 mM pH 6.0 potassium phosphate monobasic, do not allow to dry. Mix 1 mL serum with 30 μ L 10 μ g/mL IS in water, add 1 mL 100 mM pH 6.0 potassium phosphate monobasic buffer, mix well. Add the sample to the SPE disc, wash with 500 μ L 1 M acetic acid, wash with 500 μ L MeOH, dry under vacuum for 5 min. Elute with two 300 μ L portions of MeCN:triethylamine 100:2. Evaporate the eluate under a stream of nitrogen, dissolve the residue in 800 μ L mobile phase, inject a 100 μ L aliquot.

HPLC VARIABLES**Guard column:** 15 \times 1 opti-guard column RP C8**Column:** 250 \times 4.6 10 μ m Chiralcel OD-R (Optimize Technologies, USA)**Mobile phase:** MeCN:300 mM aqueous sodium perchlorate 42:58**Flow rate:** 0.5**Injection volume:** 100**Detector:** UV 210

CHROMATOGRAM**Retention time:** 20.2 (R), 22.9 (S)**Internal standard:** diphenhydramine (13.8)**Limit of detection:** 10 ng/mL**Limit of quantitation:** 15 ng/mL

OTHER SUBSTANCES**Extracted:** metabolites

KEY WORDS

serum; SPE; chiral

REFERENCE

Liu,J.; Stewart,J.T. Quantitation of trimipramine enantiomers in human serum by enantioselective high-performance liquid chromatography and mixed-mode disc solid-phase extraction, *J.Chromatogr.B*, **1997**, 700, 175-182.

SAMPLE**Matrix:** blood**Sample preparation:** 2 mL Plasma + 800 ng clomipramine in MeOH + 2 mL 1 M NaOH + 5 mL hexane:isoamyl alcohol 99:1, shake mechanically for 15 min, centrifuge at 1686 g for 5 min. Remove the organic phase and add it to 200 μ L 0.05% orthophosphoric acid, shake for 15 min, centrifuge for 5 min, inject a 50 μ L aliquot of the aqueous phase.

HPLC VARIABLES**Guard column:** μ Bondapak/Porasil**Column:** μ Bondapak C18**Mobile phase:** MeCN:buffer 40:60 (Buffer was 13.68 g KH_2PO_4 in 2 L water, adjusted to pH 4.7 with dilute KOH.)**Column temperature:** 50**Flow rate:** 2**Injection volume:** 50**Detector:** UV 254

CHROMATOGRAM**Internal standard:** clomipramine**Limit of detection:** 3 ng

KEY WORDS

plasma

REFERENCE

Wong,S.H.; Stolarun,S.L. Liquid-chromatographic analysis of trimipramine in plasma, *Clin.Chem.*, **1981**, 27, 1101.

SAMPLE

Matrix: blood

Sample preparation: 1 mL Serum + 200 μ L 10 μ g/mL protriptyline in water + 200 μ L 80 g/L NaHCO₃ + 5 mL hexane, vortex for 15 s, centrifuge for 5 min. Remove the hexane layer and evaporate it in a stream of nitrogen at 60°. Reconstitute in 100 μ L mobile phase, vortex for 15 s, inject a 50 μ L aliquot.

HPLC VARIABLES

Column: 300 \times 4 10 μ m μ Bondapak CN

Mobile phase: MeCN:MeOH:5 mM phosphate buffer 60:15:25, adjusted to pH 7.0

Flow rate: 2

Injection volume: 50

Detector: UV 254

CHROMATOGRAM

Retention time: 2.33

Internal standard: protriptyline (12.20)

Limit of detection: 6 ng/mL

OTHER SUBSTANCES

Extracted: imipramine, doxepin, amitriptyline, desmethyldoxepin, nortriptyline, desipramine, chlorpromazine, procainamide, thioridazine, propranolol, propoxyphene, disopyramide, maprotiline

Noninterfering: caffeine, theophylline, salicylic acid, chlordiazepoxide, methaqualone, diazepam, acetaminophen

Interfering: trifluoperazine

KEY WORDS

serum

REFERENCE

Koteel,P.; Mullins,R.E.; Gadsden,R.H. Sample preparation and liquid-chromatographic analysis for tricyclic antidepressants in serum, *Clin.Chem.*, **1982**, *28*, 462-466.

SAMPLE

Matrix: blood

Sample preparation: Evaporate 200 μ L 1 μ g/mL clomipramine in MeOH into a tube, add 2 mL plasma, add 2 mL pH 10 Titrisol buffer (Merck), add 8 mL diethyl ether, shake for 15 min, centrifuge at 2800 g for 5 min. Remove the organic phase and shake it with 100 μ L 50 mM phosphoric acid for 15 min, centrifuge at 2800 g for 10 s. Remove the aqueous layer and vortex it with 2 mL diethyl ether for 10 s, centrifuge at 2800 g. Discard the organic layer and inject a 10-50 μ L aliquot of the aqueous layer.

HPLC VARIABLES

Column: 300 \times 3.9 10 μ m μ Bondapak C18

Mobile phase: MeCN:25 mM KH₂PO₄:water 45:50:5

Flow rate: 1

Injection volume: 10-50

Detector: UV 254

CHROMATOGRAM

Retention time: 10.10

Internal standard: clomipramine (13)

Limit of detection: 4-5 ng/mL

OTHER SUBSTANCES

Extracted: imipramine, desipramine

Noninterfering: nortriptyline, triazolam, monodesmethyltrimipramine, flunitrazepam, alimemazine, alprazolam, amineptine, caffeine, carbamazepine, citalopram, desmethylflunitrazepam, diazepam, dibenzepine, estazolam, ethyl loflazepate, indalpine, loprazolam, lorazepam, meprobamate, nitrazepam, nordiazepam, nortriptyline, oxazepam, viloxazine

Interfering: amitriptyline, clobazam, levomepromazine

KEY WORDS

plasma

REFERENCE

Pok Phak,R.; Conquy,T.; Gouezo,F.; Viala,A.; Grimaldi,F. Determination of metapramine, imipramine, trimipramine and their major metabolites in plasma by reversed-phase column liquid chromatography, *J.Chromatogr.*, **1986**, 375, 339–347.

SAMPLE

Matrix: blood

Sample preparation: Condition a Bond Elut C-18 SPE cartridge twice with MeOH and twice with water. 500 μ L Serum + 50 μ L 1 μ g/mL N-propionylprocainamide in 2.5 mM HCl, add to SPE cartridge, wash with 2 volumes water, wash with 2 volumes 0.1 M acetic acid, wash with 1 volume MeOH:2.5 mM HCl 10:90. Add 200 μ L 10 mM acetic acid and 5 mM diethylamine in MeOH to column, let stand 1 min, elute under vacuum, repeat, evaporate eluents to dryness under nitrogen at room temperature, reconstitute in 100 μ L mobile phase, inject a 40 μ L aliquot.

HPLC VARIABLES

Guard column: Pelliguard LC-CN (Supelco)

Column: 150 \times 4.6 5 μ m Supelcosil LC-PCN

Mobile phase: MeCN:MeOH:10 mM pH 7.0 phosphate buffer 58:14:28

Flow rate: 1.2

Injection volume: 40

Detector: UV 254

CHROMATOGRAM

Retention time: 6.9

Internal standard: N-propionylprocainamide (6)

Limit of quantitation: 25 ng/mL

OTHER SUBSTANCES

Extracted: amitriptyline, desipramine, doxepin, imipramine, nortriptyline, protriptyline

Simultaneous: atropine, butalbital, chlorpromazine, maprotiline, methadone, norpropoxyphene, phenylpropanolamine, prochlorperazine, promethazine, propranolol, quinidine, trifluoperazine, trimeprazine

Noninterfering: acetaminophen, allopurinol, amikacin, amoxapine, amytal, bretylium, caffeine, carbamazepine, carisoprodol, chloramphenicol, chlordiazepoxide, chlorpropamide, clonazepam, codeine, diazepam, disopyramide, droperidol, ethinamate, ethinamate, ethosuximide, fluphenazine, flurazepam, furosemide, gentamicin, haloperidol, hydrochlorothiazide, hydroxyzine, ibuprofen, kanamycin, lidocaine, loxapine, meperidine, mephobarbital, meprobamate, methaqualone, methotrexate, morphine, nafcillin, naloxone, neomycin, perphenazine, phenacetin, phenobarbital, phenytoin, prazepam, primidone, procaine, propoxyphene, reserpine, salicylamide, salicylic acid, secobarbital, spironolactone, theophylline, thiopental, thioridazine, tobramycin, valproic acid, verapamil

Interfering: hydroxyamitriptyline, procainamide

KEY WORDS

serum; SPE

REFERENCE

Lin,W.-N.; Frade,P.D. Simultaneous quantitation of eight tricyclic antidepressants in serum by high-performance liquid chromatography, *Ther.Drug Monit.*, **1987**, 9, 448–455.

SAMPLE

Matrix: blood

Sample preparation: Inject 200 μ L serum onto column A and elute with mobile phase A for 10 min then back-flush column A onto column B with mobile phase B for 4 min. Elute column B with mobile phase B and monitor the effluent. Remove column A from circuit and wash with MeCN:water 60:40 for 6 min then with mobile phase A for 10 min.

HPLC VARIABLES

Column: A 40 × 4 TSK precolumn PW (Tosoh); B 150 × 4 TSKgel ODS-80TM (Tosoh)

Mobile phase: A 50 mM pH 7.5 potassium phosphate; B MeCN:100 mM pH 2.7 potassium phosphate 32.5:67.5, containing 0.2 g/L sodium 1-heptanesulfonate

Flow rate: 1

Injection volume: 200

Detector: UV 210

CHROMATOGRAM

Retention time: 19

Limit of detection: 10 ng/mL

OTHER SUBSTANCES

Extracted: amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline

KEY WORDS

serum; column-switching; use gradient to determine metabolites

REFERENCE

Matsumoto,K.; Kanba,S.; Kubo,H.; Yagi,G.; Iri,H.; Yuki,H. Automated determination of drugs in serum by column-switching high-performance liquid chromatography. IV. Separation of tricyclic and tetracyclic antidepressants and their metabolites, *Clin.Chem.*, **1989**, 35, 453–456.

SAMPLE

Matrix: blood

Sample preparation: 2 mL Plasma + 20 ng chlorpromazine + 10 mL hexane:isoamyl alcohol 98:2, vortex, shake for 15 min, centrifuge at 840 g at 0–2° for 15 min. Remove the upper organic layer and evaporate it to dryness under a stream of nitrogen at 50°, reconstitute the residue in 100 µL mobile phase, inject an aliquot.

HPLC VARIABLES

Column: 250 × 4.6 5 µm Spherisorb nitrile

Mobile phase: MeCN:MeOH:buffer 1:1:1 (Buffer was K₂HPO₄ adjusted to pH 6.5 with orthophosphoric acid.)

Column temperature: 40

Flow rate: 0.8

Detector: E, ESA Coulochem Model 5100A, electrode 1 +0.3 V. electrode 2 +0.85 V

CHROMATOGRAM

Retention time: 15

Internal standard: chlorpromazine (17)

Limit of quantitation: 1 ng/mL

OTHER SUBSTANCES

Extracted: metabolites

KEY WORDS

plasma; pharmacokinetics

REFERENCE

Gulaid,A.A.; Jahn,G.A.; Maslen,C.; Dennis,M.J. Simultaneous determination of trimipramine and its major metabolites by high-performance liquid chromatography, *J.Chromatogr.*, **1991**, 566, 228–233.

SAMPLE

Matrix: blood

Sample preparation: Condition a 1 mL BondElut C18 SPE cartridge with 1 mL 1 M HCl, 1 mL MeOH, 1 mL water, and 1 mL 1% potassium carbonate. 700 µL Serum + 50 µL 5 µg/mL protriptyline in 5% potassium bicarbonate + 700 µL MeCN, vortex, centrifuge at 1500 g for 5 min, add supernatant to SPE cartridge (at ca. 1 mL/min). Wash with 2 mL water and 1 mL

MeCN, elute with 250 μ L MeOH:35% perchloric acid 20:1 by gravity (10 min) then centrifuge for 20 s to remove rest of eluant, inject a 50 μ L aliquot of the eluate.

HPLC VARIABLES

Guard column: 15 mm 7 μ m Brownlee RP-8

Column: 150 \times 4.6 5 μ m Ultrasphere Octyl

Mobile phase: MeCN:water 37.5:62.5 containing 0.5 g/L tetramethylammonium perchlorate and 0.5 mL/L 7% perchloric acid

Flow rate: 1.5

Injection volume: 50

Detector: UV 215

CHROMATOGRAM

Retention time: 9.6

Internal standard: protriptyline (6.6)

Limit of quantitation: 5 ng/mL

OTHER SUBSTANCES

Extracted: amitriptyline, clomipramine, desipramine, doxepin, fluoxetine, fluvoxamine, imipramine, maprotiline, nortriptyline

KEY WORDS

serum; SPE

REFERENCE

Gupta, R.N. An improved solid phase extraction procedure for the determination of antidepressants in serum by column liquid chromatography, *J.Liq.Chromatogr.*, **1993**, 16, 2751-2765.

SAMPLE

Matrix: blood

Sample preparation: 1 mL Serum or plasma + 200 μ L 0.33 M NaOH, shake 5 s, add 7 mL n-hexane:iso-amyl alcohol 985:15, shake 20 min, centrifuge at 2100 g for 5 min. Remove organic phase and add 200 μ L 0.1 M HCl to it, shake for 1 min, discard organic phase, inject 30 μ L of aqueous phase.

HPLC VARIABLES

Guard column: 10 mm 10 μ m Bischoff C18

Column: 125 \times 4 5 μ m Ecotube Nucleosil C8

Mobile phase: MeCN:water:diethylamine:PicB5 370:630:0.4:25 (PicB5 is water-MeOH-1-pentanesulfonic acid.)

Column temperature: 55

Flow rate: 1.7

Injection volume: 30

Detector: UV 230

CHROMATOGRAM

Retention time: 8.4

Internal standard: trimipramine

Limit of detection: 10 ng/mL

OTHER SUBSTANCES

Extracted: fluoxetine, norfluoxetine

Noninterfering: alprazolam, bromazepam, clorazepate, diazepam, flunitrazepam, lorazepam, oxazepam, triazolam, amitriptyline, clomipramine, desipramine, imipramine, fluvoxamine, nortriptyline

KEY WORDS

serum; plasma; trimipramine is IS

REFERENCE

el Maanni,A.; Combourieu,I.; Bonini,M.; Creppy,E.E. Fluoxetine, an antidepressant, and norfluoxetine, its metabolite, determined by HPLC with a C_8 column and ultraviolet detection, *Clin.Chem.*, **1993**, *39*, 1749–1750.

SAMPLE

Matrix: blood

Sample preparation: Automated SPE by ASPEC system. Condition a C18 Clean-Up SPE cartridge (CEC 18111, Worldwide Monitoring) with 2 mL MeOH then 2 mL water. 1 mL Plasma + 1 mL 400 ng/mL protriptyline in water, vortex, add to column, wash with 3 mL water, wash with 3 mL 750 mL/L methanol. Elute with three aliquots of 300 μ L 0.1 M ammonium acetate in MeOH. Add 0.5 mL 0.5 M NaOH and 4 mL 50 mL/L isopropanol in heptane to eluate, mix thoroughly. Allow 5 min for phase separation. Remove upper heptane phase and add it to 300 μ L 0.1 M phosphoric acid (pH 2.5), mix, separate, inject a 100 μ L aliquot of the aqueous phase.

HPLC VARIABLES

Guard column: LC-8-DB (Supelco)

Column: 150 \times 4.6 LC-8-DB (Supelco)

Mobile phase: MeCN:buffer 35:65 (Buffer was 10 mL/L triethylamine in water adjusted to pH 5.5 with glacial acetic acid.)

Flow rate: 2

Injection volume: 100

Detector: UV 228

CHROMATOGRAM

Retention time: 5.9

Internal standard: protriptyline (4)

OTHER SUBSTANCES

Extracted: chlordiazepoxide, chlorimipramine, chlorpromazine, desipramine, dextromethorphan, diazepam, diphenhydramine, doxepin, encainide, fentanyl, flecainide, fluoxetine, flurazepam, haloperidol, hydroxyethylflurazepam, ibuprofen, imipramine, lidocaine, maprotiline, methadone, methaqualone, mexiletine, midazolam, norchlorimipramine, nordiazepam, nordoxepin, norfluoxetine, nortriptyline, norverapamil, pentazocine, promazine, propafenone, propoxyphene, propranolol, protriptyline, quinidine, temazepam, trazodone, verapamil

Noninterfering: acetaminophen, acetylmorphine, amiodarone, amobarbital, amphetamine, ben-droflumethiazide, benzocaine, benzoylecgonine, benzthiazide, butalbital, carbamazepine, chlorothiazide, clonazepam, cocaine, codeine, cotinine, cyclosporine, cyclothiazide, desalkylflurazepam, diamorphine, dicumerol, ephedrine, ethacrynic acid, ethanol, ethchlorvynol, ethosuximide, furosemide, glutethimide, hydrochlorothiazide, hydrocodone, hydroflumethiazide, hydromorphone, lorazepam, mephentermine, meprobamate, methamphetamine, metharbital, methoxsalen, methoxyphenteramine, methsuximide, methyleclothiazide, metoprolol, MHPG, monoacetylmorphine, morphine, normethsuximide, oxazepam, oxycodone, oxymorphone, pentobarbital, phenacyclidine, phenteramine, phenylephrine, phenytoin, polythiazide, primidone, prochlorperazine, salicylic acid, sulfanilamide, THC-COOH, theophylline, thiazolam, thiopental, thioridazine, tocinide, trichloromethiazide, trifluoperazine, valproic acid, warfarin

Interfering: acetazolamide, amitriptyline

KEY WORDS

plasma; SPE

REFERENCE

Nichols,J.H.; Charlson,J.R.; Lawson,G.M. Automated HPLC assay of fluoxetine and norfluoxetine in serum, *Clin.Chem.*, **1994**, *40*, 1312–1316.

SAMPLE

Matrix: blood

Sample preparation: 990 μ L Serum + 10 μ L 14 μ g/mL trimipramine in MeOH. Inject onto column A and elute with mobile phase A for 15 min then elute contents of column A onto column B with mobile phase B, monitor the effluent from column B.

HPLC VARIABLES

Column: A 10×4.6 10 μm Hypersil MOS C8; B 250×4.6 5 μm Nucleosil 100 CN

Mobile phase: A MeOH:water 5:95; B MeOH:MeCN:10 mM pH 6.8 potassium phosphate buffer 188:5778:235 (sic, perhaps 188:577:235 ?)

Detector: UV 214

CHROMATOGRAM

Internal standard: trimipramine

KEY WORDS

serum; trimipramine is IS; column-switching

REFERENCE

Rao,M.L.; Staberock,U.; Baumann,P.; Hiemke,C.; Deister,A.; Cuendet,C.; Amey,M.; Härtter,S.; Kraemer,M. Monitoring tricyclic antidepressant concentrations in serum by fluorescence polarization immunoassay compared with gas chromatography and HPLC, *Clin.Chem.*, **1994**, *40*, 929–933.

SAMPLE

Matrix: blood

Sample preparation: Centrifuge plasma or serum at 3000 g for 5 min, inject a 100 μL aliquot on to column A and elute to waste with mobile phase A, after 5 min elute the contents of column A on to column B with mobile phase B, after 3 min remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B.

HPLC VARIABLES

Column: A 10×4 10 μm Hypersil CPS; B 20×4.6 5 μm Spherisorb CN + 250×4.6 5 μm Spherisorb CN

Mobile phase: A MeCN:water 5:95; B MeCN:MeOH:8 mM pH 6.2 phosphate buffer 58:19:23

Flow rate: 1.5

Injection volume: 100

Detector: UV 214

CHROMATOGRAM

Retention time: 15

Limit of quantitation: 10 ng/mL

OTHER SUBSTANCES

Noninterfering: biperiden, chlorprothixene, diazepam, flunitrazepam, fluvoxamine, haloperidol, lorazepam, maprotiline, moclobemide, paroxetine, perazine, risperidone

KEY WORDS

plasma; serum; column-switching

REFERENCE

Härtter,S.; Hermes,B.; Hiemke,C. Automated determination of trimipramine and N-desmethyltrimipramine in human plasma or serum by HPLC with on-line solid phase extraction, *J.Liq.Chromatogr.*, **1995**, *18*, 3495–3505.

SAMPLE

Matrix: blood

Sample preparation: 2 mL Whole blood or plasma + 2 mL buffer + 5 mL chloroform:isopropanol: n-heptane 60:14:26, shake gently horizontally for 10 min, centrifuge at 2800 g for 10 min. Remove the lower organic layer and evaporate it to dryness under vacuum at 45°, reconstitute the residue in 100 μL mobile phase, centrifuge at 2800 g for 5 min, inject a 50 μL aliquot of the supernatant. (Buffer was saturated ammonium chloride solution 25% diluted with water, adjusted to pH 9.5 with 25% ammonia solution.)

HPLC VARIABLES

Column: 300×3.9 4 μm NovaPack C18

Mobile phase: MeOH:THF:buffer 65:5:30 (Buffer was 0.68 g/L (10 mM (sic)) KH_2PO_4 adjusted to pH 2.6 with concentrated orthophosphoric acid.) (At the end of each session wash the column with water for 1 h and MeOH for 1 h, re-equilibrate for 30 min.)

Column temperature: 30

Flow rate: 0.8

Injection volume: 50

Detector: UV 251

CHROMATOGRAM

Retention time: 9.78

Limit of detection: <120 ng/mL

KEY WORDS

whole blood; plasma; interferences may occur—compounds (all of which are extracted) elute in this order tenoxicam; iproniazid; methocarbamol; methotrexate; caffeine; nialamide; colchicine; cytarabine; benzoylecgonine; acetaminophen; diazoxide; dacarbazine; sulfinpyrazole; flumazenil; sulpride; morphine; atenolol; toloxatone; terbutaline; albuterol; phenobarbital; ranitidine; tiapride; phenol; chlormezanone; aspirin; metformin; ritodrine; codeine; sultopride; amisulpride; naltrexone; lisinopril; viloxazine; nizatidine; nalorphine; mephenesin; naloxone; sotalol; carteolol; procainamide; carbamazepine; bromazepam; nalbuphine; nadolol; procabazine; dihydralazine; omeprazole; strychnine; acebutolol; glutethimide; chlorpropamide; glipizide; triazolam; prazosin; flunitrazepam; clonazepam; metoclopramide; melphalan; estazolam; tolbutamide; ephedrine; clonidine; pindolol; clobazam; minoxidil; disopyramide; nitrazepam; dextromethorphan; tofisopam; zopiclone; debrisoquine; sulindac; alprazolam; cycloguanil; lorazepam; methaqualone; ketamine; piroxicam; metoprolol; nifedipine; quinine; mephentermine; prilocaine; pentazocine; oxazepam; tiaprofenic acid; quinidine; celiprolol; ajmaline; yohimbine; lidocaine; secobarbital; viloxazine; mepivacaine; meperidine; doxylamine; labetalol; temazepam; amodiaquine; benperidol; droperidol; hydroxychloroquine; zolpidem; ketoprofen; alminoprofen; cicletanine; moclobemide; chloroquine; cocaine; timolol; nomifensine; ticlopidine; acenocoumarol; videsine; mexiletine; dipyrindamole; trazodone; pipamperone; pyrimethamine; benazepril; vincristine; trimipramine; chlordiazepoxide; oxprenolol; warfarin; clorazepate; flecainide; phenacyclidine; thiopental; fenfluramine; metipranolol; triprolidine; naproxen; buprenorphine; verapamil; buspirone; tianeptine; midazolam; bupivacaine; carbinoxamine; loprazolam; cetirizine; chlorpheniramine; moperone; cibenzoline; medifoxamine; astemizole; vinblastine; nicardipine; bisoprolol; diltiazem; glibornuride; reserpine; aconitine; nitrendipine; diazepam; mianserin; ramipril; haloperidol; tetracaine; alprenolol; aceprometazine; glibenclamide; chlorophenacinone; doxepin; nimodipine; diphenhydramine; cyclizine; histapyrodine; phenylbutazone; demexiptiline; clozapine; proguanil; trifluoperidol; medazepam; cyamemazine; bumadizone; suriclone; propranolol; acepromazine; dothiepin; dextromoramide; fenopropfen; dextropropoxyphene; loxapine; betaxolol; propafenone; promethazine; thioproperazine; methadone; amoxapine; quinupramine; opipramol; cyproheptadine; brompheniramine; mefenidramine; protriptyline; flurbipofen; tetrazepam; zorubicin; prazepam; alimemazine; loperamide; imipramine; desipramine; levomepromazine; hydroxyzine; niflumic acid; penbutolol; fluvoxamine; pimozide; daunorubicin; indomethacin; maprotiline; tropatenine; etodolac; fluoxetine; amitriptyline; nortriptyline; tiocloamarol; diclofenac; mefloquine; trimipramine; chlorambucil; lidoflazine; ibuprofen; floctafenine; alpidem; loratadine; chlorpromazine; clomipramine; carpi-pramine; thioridazine; fentiazac; clemastine; mefenamic acid; fluphenazine; prochlorperazine; penfluridol; bepridil; terfenadine; trifluoperazine

REFERENCE

Tracqui, A.; Kintz, P.; Mangin, P. Systematic toxicological analysis using HPLC/DAD, *J. Forensic Sci.*, **1995**, *40*, 254–262.

SAMPLE

Matrix: blood, tissue

Sample preparation: Blood or serum. 1 mL Blood or serum + 1 µg cyanopramine + 1 mL water, vortex, add 1 mL 200 mM sodium carbonate, vortex, add 6 mL hexane:1-butanol 95:5, gently agitate for 30 min, centrifuge at 2500 g for 5 min. Remove the organic layer and add it to 100 µL 0.2% phosphoric acid, agitate gently for 30 min, centrifuge for 5 min. Remove the organic layer and inject a 30 µL aliquot of the aqueous layer. Liver homogenate. 0.5 mL Liver homogenate + 10 µg cyanopramine + 500 µL 2% sodium tetraborate + 8 mL hexane:1-butanol 95:5, gently agitate for 30 min, centrifuge at 2500 g for 5 min. Remove the organic layer and add it to 400 µL 0.2% phosphoric acid, agitate gently for 30 min, centrifuge for 5 min. Remove the organic layer and inject a 30 µL aliquot of the aqueous layer.

HPLC VARIABLES

Guard column: 15 × 3.2 7 µm RP-18 Newguard (Applied Biosystems)

Column: 100 × 4.6 5 µm Brownlee Spheri-5 RP-18

Mobile phase: MeCN:100 mM NaH₂PO₄:diethylamine 40:57.5:2.5

Flow rate: 2

Injection volume: 30

Detector: UV 220

CHROMATOGRAM

Retention time: 22.0

Internal standard: cianopramine (8.93)

Limit of detection: 50 ng/mL

OTHER SUBSTANCES

Simultaneous: amitriptyline, amoxapine, brompheniramine, chlorpheniramine, chlorpromazine, clomipramine, cyproheptadine, desipramine, diphenhydramine, dothiepin, doxepin, fluoxetine, haloperidol, imipramine, loxapine, maprotiline, meperidine, mesoridazine, methadone, metoclopramide, mianserin, moclobemide, nomifensine, nordoxepin, norfluoxetine, norpropoxyphene, northiaden, nortriptyline, pentobarbital, pheniramine, propoxyphene, propranolol, protriptyline, quinidine, quinine, sulforidazine, thioridazine, thiothixene, tranlycypromine, trazodone, trihexyphenidyl, triprolidine

Noninterfering: dextromethorphan, norphethidine, phenoxybenzamine, prochlorperazine, trifluoperazine

Interfering: promethazine, benztrapine

KEY WORDS

serum; whole blood; liver

REFERENCE

McIntyre, I.M.; King, C.V.; Skafidis, S.; Drummer, O.H. Dual ultraviolet wavelength high-performance liquid chromatographic method for the forensic or clinical analysis of seventeen antidepressants and some selected metabolites, *J.Chromatogr.*, **1993**, 621, 215–223.

SAMPLE

Matrix: blood, urine

Sample preparation: Plasma. 1 mL Plasma + 100 µL MeOH + 1 mL 200 mM pH 9.8 carbonate buffer + 5 mL hexane, rotate for 15 min, centrifuge at 3000 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 50°, reconstitute the residue in 150 µL mobile phase, inject a 75 µL aliquot. Urine. 1 mL Urine + 1 mL β-glucuronidase (7200 Fishman Units) in 20 mM pH 6.5 phosphate buffer, heat at 37° for 24 h, add 100 µL 10 M NaOH, add 5 mL hexane, rotate for 15 min, centrifuge at 3000 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 50°, reconstitute the residue in 1 mL mobile phase, inject a 50 µL aliquot.

HPLC VARIABLES

Guard column: 20 × 4.6 C18 base-deactivated silica (BDS) (Keystone)

Column: 50 × 4.6 5 µm C18 base-deactivated silica (BDS) (Keystone)

Mobile phase: MeCN:water 90:10 containing 0.1% formic acid and 10 mM ammonium acetate

Flow rate: 1

Injection volume: 50–75

Detector: MS, PE Sciex API III, heated nebulized interface, corona discharge needle +4 µA, nebulizer probe 500°, nebulizing gas was air at 2 L/min and 80 psi, curtain gas flow was nitrogen at 0.9 L/min, sampling orifice +45 V, dwell time 400 ms, interface heater 60°, electron multiplier–3.7 kV, collision gas was argon 355 × 10¹² atoms/cm², first quadrupole filter admits m/z 276 (cyclobenzaprine) and 295 (trimipramine, collisional fragmentation at second filter, monitor m/z 215 (cyclobenzaprine) and 208 (trimipramine) at third quadrupole filter

CHROMATOGRAM

Retention time: 2.2

Internal standard: trimipramine

OTHER SUBSTANCES

Extracted: cyclobenzaprine

KEY WORDS

plasma; trimipramine is IS

REFERENCE

Constanzer,M.; Chavez,C.; Matuszewski,B. Development and comparison of high-performance liquid chromatographic methods with tandem mass spectrometric and ultraviolet absorbance detection for the determination of cyclobenzaprine in human plasma and urine, *J.Chromatogr.B*, **1995**, 666, 117–126.

SAMPLE

Matrix: blood, urine

Sample preparation: Plasma. 1 mL Plasma + 100 μ L MeOH + 1 mL 200 mM pH 9.8 carbonate buffer + 5 mL hexane, rotate for 15 min, centrifuge at 3000 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 50°, reconstitute the residue in 300 μ L mobile phase, inject a 150 μ L aliquot. Urine. 1 mL Urine + 1 mL β -glucuronidase (7200 Fishman Units) in 20 mM pH 6.5 phosphate buffer, heat at 37° for 24 h, add 100 μ L 10 M NaOH, add 5 mL hexane, rotate for 15 min, centrifuge at 3000 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 50°, reconstitute the residue in 300 μ L mobile phase, inject a 150 μ L aliquot.

HPLC VARIABLES

Guard column: 20 mm long C18 base-deactivated silica (BDS) (Keystone)

Column: 250 \times 4.6 5 μ m C18 base-deactivated silica (BDS) (Keystone)

Mobile phase: MeCN:buffer 50:50 (plasma) or 43:57 (urine) (Buffer was 0.085% phosphoric acid adjusted to pH 6.5 with triethylamine.)

Flow rate: 1

Injection volume: 150

Detector: UV 229

CHROMATOGRAM

Retention time: 10.5 (plasma), 12.8 (urine)

Internal standard: trimipramine

OTHER SUBSTANCES

Extracted: cyclobenzaprine

KEY WORDS

plasma; trimipramine is IS

REFERENCE

Constanzer,M.; Chavez,C.; Matuszewski,B. Development and comparison of high-performance liquid chromatographic methods with tandem mass spectrometric and ultraviolet absorbance detection for the determination of cyclobenzaprine in human plasma and urine, *J.Chromatogr.B*, **1995**, 666, 117–126.

SAMPLE

Matrix: blood, urine

Sample preparation: Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 μ L MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) μ L aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200–350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

HPLC VARIABLES

Guard column: 20 mm long Symmetry C18

Column: 250 \times 4.6 5 μ m Symmetry C8 (Waters)

Mobile phase: Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

Column temperature: 30

Flow rate: 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

Injection volume: 10-30

Detector: UV 200.5

CHROMATOGRAM

Retention time: 15.943

KEY WORDS

whole blood

REFERENCE

Gaillard, Y.; Pépin, G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J. Chromatogr. A*, **1997**, 763, 149-163.

SAMPLE

Matrix: solutions

Sample preparation: Prepare a 10 µg/mL solution in MeOH, inject a 20 µL aliquot.

HPLC VARIABLES

Column: 125 × 4.9 Spherisorb S5W silica

Mobile phase: MeOH containing 10 mM ammonium perchlorate and 1 mL/L 100 mM NaOH in MeOH, pH 6.7

Flow rate: 2

Injection volume: 20

Detector: E, LeCarbone, V25 glassy carbon electrode, + 1.2 V

CHROMATOGRAM

Retention time: 3.2

OTHER SUBSTANCES

Also analyzed: acebutolol, acepromazine, acetophenazine, N-acetylprocainamide, albuterol, alprenolol, amethocaine, amiodarone, amitriptyline, antazoline, atenolol, azacyclonal, bamethan, benactyzine, benperidol, benzethidine, benzocaine, benzocetamine, benzphetamine, benzquinamide, bromhexine, bromodiphenhydramine, bromperidol, brompheniramine, brompromazine, buclizine, bufotenine, bupivacaine, buprenorphine, butacaine, butethamate, chlorcyclizine, chlorpheniramine, chlorphenoxamine, chlorprenaline, chlorpromazine, chlorprothixene, cimetidine, cinchonidine, cinnarizine, clemastine, clomipramine, clonidine, cocaine, cyclazocine, cyclizine, cyclopentamine, cyproheptadine, deserpidine, desipramine, dextromoramide, dextropropoxyphene, dicyclomine, diethylcarbamazine, diethylpropion, diethylthiambutene, dihydroergotamine, dimethindene, dimethothiazine, diphenhydramine, diphenoxylate, dipiprone, diprenorphine, dipyrindamole, disopyramide, dothiepin, doxapram, doxepin, doxylamine, droperidol, ephedrine, ergocornine, ergocristine, ergocristinine, ergocryptine, ergometrine, ergosine, ergosinine, ergotamine, ethopropazine, etorphine, etoxeridine, fenethazine, fenfluramine, fenoterol, fentanyl, flavoxate, fluopromazine, flupenthixol, fluphenazine, flurazepam, haloperidol, hydroxyzine, hyoscine, ibogaine, imipramine, indapamine, iprindole, isothipendyl, isoxsuprine, ketanserine, laudanosine, lidocaine, lofepramine, loxapine, maprotiline, mecamlamine, meclorphenoxate, meclozine, medazepam, mephentermine, mepivacaine, meptazinol, mepyramine, mesoridazine, metaraminol, methadone, methamphetamine, methapyrilene, methdilazene, methotrimeprazine, methoxamine, methoxyphenamine, methoxypromazine, methylephedrine, methylergonovine, methysergide, metoclopramide, metopimazine, metoprolol, mianserin, morazone, nadolol, naltrexone, naloxone, naphazoline, nicotine, nifedipine, nomifensine, nortriptyline, noscapine, orphenadrine, oxeladin, oxprenolol, oxymetazoline, papaverine, pargyline, pecazine, penbutolol, pentazocine, penthienate, pericyazine, perphenazine, phenadoxone, phenampromide, phenazocine, phenbutrazate, phendimetrazine, phenelzine, phenglutarimide, phenindamine, pheniramine, phenmetrazine, phenomorphan, phenoperidine, phenothiazine, phenoxybenzamine, phentolamine, phenylephrine, phenyltoloxamine, physostigmine, piminodine, pimozide, pindolol, pipamazine, pipazethate, piperacetazine, piperidolate, pipradol, pirenzepine, piritramide, pizotifen, practolol, pramoxine, prazosin, prenylamine, prilocaine, primaquine, proadifen, procainamide, procaine, prochlorperazine, procyclidine, proheptazine, prolintane, promazine, promethazine, pronethalol, properidine, propiomazine, propranolol, prothipendyl, protriptyline, proxymetacaine, pseudoephedrine, pyrimethamine, quin-

idine, quinine, ranitidine, rescinnamine, sotalol, tacrine, terazosin, terbutaline, terfenadine, thenyldiamine, theophylline, thiethylperazine, thiopropazate, thioproperazine, thioridazine, thiothixene, thonzylamine, timolol, tocainide, tolpropamine, tolycaine, tranlycypromine, trazodone, trifluoperazine, trifluoperidol, trimeperidine, trimeprazine, trimethobenzamide, trimethoprim, tripeleennamine, triprolidine, tryptamine, verapamil, xylometazoline

REFERENCE

Jane,I.; McKinnon,A.; Flanagan,R.J. High-performance liquid chromatographic analysis of basic drugs on silica columns using non-aqueous ionic eluents. II. Application of UV, fluorescence and electrochemical oxidation detection, *J.Chromatogr.*, **1985**, 323, 191–225.

SAMPLE

Matrix: solutions

HPLC VARIABLES

Column: 100 × 4.5 µm CHIRAL-AGP (ChromTech)

Mobile phase: Isopropanol:59 mM pH 4.0 acetate buffer 1:99

Flow rate: 0.9

Injection volume: 20

Detector: UV 225

CHROMATOGRAM

Retention time: k' 4.43, 7.32 (enantiomers)

KEY WORDS

chiral

REFERENCE

Hermansson,J.; Grahn,A. Optimization of the separation of enantiomers of basic drugs. Retention mechanisms and dynamic modification of the chiral bonding properties on an α_1 -acid glycoprotein column, *J.Chromatogr.A*, **1995**, 694, 57–69.

SAMPLE

Matrix: solutions

Sample preparation: Inject an aliquot of a 200 µM solution in MeOH.

HPLC VARIABLES

Column: 100 × 4.7 µm Hypercarb (Shandon)

Mobile phase: MeOH containing 5 mM N-benzoyloxycarbonylglycyl-L-proline and 4.5 mM NaOH

Column temperature: 17

Injection volume: 20

Detector: UV 270

CHROMATOGRAM

Retention time: k' 21 (first enantiomer)

KEY WORDS

chiral; $\alpha = 1.19$

REFERENCE

Huynh,N.-H.; Karlsson,A.; Pettersson,C. Enantiomeric separation of basic drugs using N-benzoyloxycarbonylglycyl-L-proline as counter ion in methanol, *J.Chromatogr.A*, **1995**, 705, 275–287.

SAMPLE

Matrix: solutions

HPLC VARIABLES

Column: 250 × 4.6 µm Supelcosil LC-DP (A) or 250 × 4.5 µm LiChrospher 100 RP-8 (B)

Mobile phase: MeCN:0.025% phosphoric acid:buffer 25:10:5 (A) or 60:25:15 (B) (Buffer was 9 mL concentrated phosphoric acid and 10 mL triethylamine in 900 mL water, adjust pH to 3.4 with dilute phosphoric acid, make up to 1 L.)

Flow rate: 0.6

Injection volume: 25

Detector: UV 229

CHROMATOGRAM

Retention time: 15.49 (A), 7.66 (B)

OTHER SUBSTANCES

Also analyzed: acebutolol, acepromazine, acetaminophen, acetazolamide, acetophenazine, albuterol, alprazolam, amitriptyline, amobarbital, amoxapine, antipyrine, atenolol, atropine, azatadine, baclofen, benzocaine, bromocriptine, brompheniramine, brotizolam, bupivacaine, buspirone, butabarbital, butalbital, caffeine, carbamazepine, cetirizine, chlorcyclizine, chlordi-azepoxide, chlormezanone, chloroquine, chlorpheniramine, chlorpromazine, chlorpropamide, chlorprothixene, chlorthalidone, chlorzoxazone, cimetidine, cisapride, clomipramine, clonazepam, clonidine, clozapine, cocaine, codeine, colchicine, cyclizine, cyclobenzaprine, dantrolene, desipramine, diazepam, diclofenac, diflunisal, diltiazem, diphenhydramine, diphenidol, diphenoxylate, dipyridamole, disopyramide, dobutamine, doxapram, doxepin, droperidol, encainide, ethidium bromide, ethopropazine, fenoprofen, fentanyl, flavoxate, fluoxetine, fluphenazine, flurazepam, flurbiprofen, fluvoxamine, furosemide, glutethimide, glyburide, guaifenesin, haloperidol, homatropine, hydralazine, hydrochlorothiazide, hydrocodone, hydromorphone, hydroxy-chloroquine, hydroxyzine, ibuprofen, imipramine, indomethacin, ketoconazole, ketoprofen, ketorolac, labetalol, levorphanol, lidocaine, loratadine, lorazepam, lovastatin, loxapine, mazin-dol, mefenamic acid, meperidine, mephénytoin, mepivacaine, mesoridazine, metaproterenol, metformin, methadone, methdilazine, methocarbamol, methotrexate, methotrimeprazine, methoxamine, methyl dopa, methylphenidate, metoclopramide, metolazone, metoprolol, me-ronidazole, midazolam, moclobemide, morphine, nadolol, nalbuphine, naloxone, naphazoline, naproxen, nifedipine, nizatidine, norepinephrine, nortriptyline, oxazepam, oxycodone, oxyme-azoline, paroxetine, pemoline, pentazocine, pentobarbital, pentoxifylline, perphenazine, phen-iramine, phenobarbital, phenol, phenolphthalein, phentolamine, phenylbutazone, phenyltolox-amine, phenytoin, pimizide, pindolol, piroxicam, pramoxine, prazepam, prazosin, probenecid, procainamide, procaine, prochlorperazine, procyclidine, promazine, promethazine, propafenone, propantheline, propiomazine, propofol, propranolol, protriptyline, quazepam, quinidine, qui-nine, racemethorphan, ranitidine, remoxipride, risperidone, salicylic acid, scopolamine, seco-barbital, sertraline, sotalol, spironolactone, sulfinpyrazone, sulindac, temazepam, terbutaline, terfenadine, tetracaine, theophylline, thiethylperazine, thiopental, thioridazine, thiothixene, timolol, tocainide, tolbutamide, tolmetin, trazodone, triamterene, triazolam, trifluoperazine, triflupromazine, trimeprazine, trimethoprim, verapamil, warfarin, xylometazoline, yohimbine, zopiclone

KEY WORDS

details of plasma extraction

REFERENCE

Koves, E.M. Use of high-performance liquid chromatography-diode array detection in forensic toxicology, *J. Chromatogr. A*, **1995**, 692, 103–119.

SAMPLE

Matrix: solutions

Sample preparation: Make up a 500 ng/mL solution in mobile phase, inject an aliquot.

HPLC VARIABLES

Column: 250 × 4.6 5 μm Sumchiral OA-4700 (S)-tert-leucine-(R)-1-(α-naphthyl)ethylamine (YMC)

Mobile phase: Hexane:1,2-dichloroethane:EtOH:trifluoroacetic acid 1200:150:100:1

Flow rate: 1

Injection volume: 100

Detector: F ex 254 em 280 (filter)

CHROMATOGRAM

Retention time: 8.4, 9.3 (enantiomers)


KEY WORDS

chiral

REFERENCE

Ponder, G.W.; Butram, S.L.; Adams, A.G.; Ramanathan, C.S.; Stewart, J.T. Resolution of promethazine, ethopropazine, trimeprazine and trimipramine enantiomers on selected chiral stationary phases using high-performance liquid chromatography, *J.Chromatogr.A*, **1995**, 692, 173–182.

Trioxsalen

Molecular formula: C₁₄H₁₂O₃**Molecular weight:** 228.25**CAS Registry No.:** 3902-71-4**Merck Index:** 9864**Lednicer No.:** 1 334**SAMPLE****Matrix:** aqueous humor, blood, tissue, vitreous humor

Sample preparation: Homogenize skin in 1 M pH 9.0 sodium borate buffer. 2 mL Whole blood, skin homogenate, aqueous humor, or vitreous humor + 5 mL 1 M pH 9.0 sodium borate buffer, mix, add 16 mL n-hexane:isopropanol 95:5, shake on a reciprocating shaker at 70-80 strokes/min for 30 min, centrifuge at 1020 g for 20 min. Remove 10 mL of the organic layer and evaporate it to dryness under a stream of nitrogen, reconstitute the residue in 50 µL EtOH, inject a 10 µL aliquot.

HPLC VARIABLES**Column:** 300 × 4 Micropak MCH-10 reverse-phase**Mobile phase:** Gradient. MeCN:water (not otherwise specified)**Flow rate:** 2**Injection volume:** 10**Detector:** UV 254**CHROMATOGRAM****Retention time:** 16.5**Internal standard:** 8-methoxypsoralen (8)**Limit of detection:** 2 ng/mL**KEY WORDS**

whole blood; guinea pig; skin; human

REFERENCE

Chakrabarti, S.G.; Grimes, P.E.; Minus, H.R.; Kenney, J.A., Jr.; Pradhan, T.K. Determination of trimethylpsoralen in blood, ophthalmic fluids, and skin, *J.Invest.Dermatol.*, **1982**, 79, 374–377.

SAMPLE**Matrix:** blood

Sample preparation: 1 mL Serum + diazepam, extract with heptane:dichloromethane 80:20.

HPLC VARIABLES**Column:** C18**Mobile phase:** MeOH:water 70:30**Detector:** UV 254 or F ex 360 em 430**CHROMATOGRAM****Limit of detection:** 1 µg/mL (UV)


KEY WORDS

serum; pharmacokinetics

REFERENCE

Stolk,L.; Siddiqui,A.H.; Cormane,R.H. Serum levels of trimethylpsoralen after oral administration, *Br.J.Dermatol.*, **1981**, 104, 443-445.

Tripelennamine

Molecular formula: $C_{16}H_{21}N_3$ **Molecular weight:** 255.36**CAS Registry No.:** 91-81-6, 6138-56-3 (citrate), 154-69-8 (HCl)**Merck Index:** 9868**Lednicer No.:** 1 51**SAMPLE****Matrix:** blood, milk

Sample preparation: Centrifuge milk at 1200 g, remove the middle aqueous layer. 1 mL Plasma or milk + 50 μ L MeOH:water 50:50 + 50 μ L 4 μ g/mL protriptyline in MeOH:water 50:50, mix, inject a 250 μ L aliquot of this mixture on to column A and elute to waste with mobile phase A. After 3 min backflush the contents of column A on to column B with mobile phase B, monitor the effluent from column B.

HPLC VARIABLES**Column:** A 37-50 μ m 10 \times 1.5 Corasil RP C18; B 100 \times 4 Techsphere 3CN (HPLC Technology)**Mobile phase:** A water; B MeCN:50 mM pH 7.2 acetate buffer 70:30**Flow rate:** A 0.8; B 0.9**Injection volume:** 250**Detector:** UV 246**CHROMATOGRAM****Retention time:** 5.2**Internal standard:** protriptyline (6.8)**Limit of detection:** 2 ng/mL**KEY WORDS**

column-switching; cow; plasma

REFERENCE

Dadgar,D.; Power,A. Applications of column-switching techniques in biopharmaceutical analysis. II. High-performance liquid chromatographic determination of tripelennamine in bovine plasma and milk, *J.Chromatogr.*, **1987**, 421, 216-222.

SAMPLE**Matrix:** formulations

Sample preparation: Tablets. Powder tablets, weigh out amount equivalent to about 10 mg, add 75 mL mobile phase, sonicate for 20 min, dilute to 100 mL with mobile phase, mix, filter (0.45 μ m) (discard first 10 mL of filtrate), inject a 20 μ L aliquot of the filtrate. Syrups, elixirs, injectables. Measure out amount equivalent to about 10 mg, add 75 mL mobile phase, sonicate for 20 min, dilute to 100 mL with mobile phase, mix, inject a 20 μ L aliquot.

HPLC VARIABLES**Column:** 300 \times 3.9 10 μ m μ Bondapak CN**Mobile phase:** MeOH:3 mM ammonium acetate 90:10**Flow rate:** 1.3**Injection volume:** 20**Detector:** UV 254